U.S. patent application number 11/544946 was filed with the patent office on 2007-04-26 for vinyl phenyl derivatives as glk activators.
This patent application is currently assigned to AstraZeneca AB. Invention is credited to Peter William Rodney Caulkett, Gordon Stuart Currie, Rodney Brian Hargreaves, Barry Raymond Hayter, Roger James.
Application Number | 20070093535 11/544946 |
Document ID | / |
Family ID | 20284651 |
Filed Date | 2007-04-26 |
United States Patent
Application |
20070093535 |
Kind Code |
A1 |
Hayter; Barry Raymond ; et
al. |
April 26, 2007 |
Vinyl phenyl derivatives as GLK activators
Abstract
The invention related to novel compounds of Formula (I) or a
salt, solvate or prodrug thereof, wherein A, R.sup.1, R.sup.2,
R.sup.3, n and m are as described in the specification, useful in
the treatment of a disease or condition mediated through
glucokinase (GLK), such as type 2 diabetes. The invention also
relates to methods for preparing compounds of Formula (I) and their
use as medicaments in the treatment of diseases mediated by
glucokinase.
Inventors: |
Hayter; Barry Raymond;
(Cheshire, GB) ; Currie; Gordon Stuart; (Cheshire,
GB) ; Hargreaves; Rodney Brian; (Cheshire, GB)
; Caulkett; Peter William Rodney; (Cheshire, GB) ;
James; Roger; (Cheshire, GB) |
Correspondence
Address: |
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON
DC
20004
US
|
Assignee: |
AstraZeneca AB
|
Family ID: |
20284651 |
Appl. No.: |
11/544946 |
Filed: |
October 10, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10482264 |
Aug 6, 2004 |
|
|
|
PCT/GB02/02903 |
Jun 24, 2002 |
|
|
|
11544946 |
Oct 10, 2006 |
|
|
|
Current U.S.
Class: |
514/355 ;
514/365; 546/315; 548/200 |
Current CPC
Class: |
C07D 413/04 20130101;
A61P 3/10 20180101; C07D 307/68 20130101; C07D 213/80 20130101;
C07D 239/28 20130101; C07D 277/56 20130101; C07D 213/78 20130101;
A61P 43/00 20180101; C07D 405/12 20130101; C07D 417/12 20130101;
A61P 3/04 20180101; C07D 213/82 20130101; C07D 413/12 20130101 |
Class at
Publication: |
514/355 ;
514/365; 546/315; 548/200 |
International
Class: |
A61K 31/455 20060101
A61K031/455; A61K 31/426 20060101 A61K031/426 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 26, 2001 |
SE |
0102299-5 |
Claims
1-18. (canceled)
19. A method for the treatment or prevention of a disease or
medical condition mediated through GLK, comprising administering to
an animal in need thereof, a compound of Formula (I) or a salt,
solvate or prodrug thereof, ##STR58## wherein A is heteroaryl; m is
0, 1 or 2; n is 0, 1, 2, 3 or 4; and n+m>0; each R.sup.1 is
independently selected from OH, --(CH.sub.2).sub.1-4OH,
--CH.sub.3-aF.sub.a, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a,
--OCH.sub.3-aF.sub.a, halo, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, NO.sub.2, NH.sub.2, --NH--C.sub.1-4alkyl,
--N-di-(C.sub.1-4alkyl), CN, formyl, phenyl and heterocyclyl
optionally substituted with C.sub.1-6alkyl; each R.sup.2 is the
group Y--X--; each X and X.sup.1 is a linker independently selected
from -Z-, --O-Z-, --O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-,
--SO-Z-, --SO.sub.2-Z-, --N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-,
--SO.sub.2N(R.sup.7)-Z-, --(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-,
--C.ident.C-Z-, --N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each Y is
independently selected from aryl-Z.sup.1-, heterocyclyl-Z.sup.1-,
C.sub.3-7cycloalkyl-Z.sup.1-, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a and
--CH(OH)CH.sub.3-aF.sub.a; wherein each Y is independently
optionally substituted with up to 3 R.sup.4 groups; each R.sup.4 is
independently selected from halo, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH,
--C(O)OC.sub.1-6alkyl, OH, phenyl optionally substituted with
C.sub.1-6alkyl or --C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--;
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, phenyl, naphthyl, heterocyclyl and
C.sub.3-7cycloalkyl; wherein R.sup.5 is optionally substituted with
halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
COOH, or --C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl
or heterocyclyl ring in R.sup.5 is optionally substituted with
halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; each Z.sup.1
is independently selected from a direct bond, C.sub.2-6alkenylene
and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; R.sup.3
is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6; R.sup.6 is
selected from hydrogen, C.sub.1-6alkyl, --OC.sub.1-6alkyl,
--SO.sub.2C.sub.1-6alkyl, and --(CH.sub.2).sub.0-3OH; each R.sup.7
is independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each a is independently 1, 2 or
3; p is 0, 1 or 2; q is 0, 1 or 2; and p+q<4.
20. A method of claim 19, wherein the compound or salt, solvate or
prodrug thereof is administered together with a pharmaceutically
acceptable diluent or carrier.
21. A compound of Formula (Ib) or a salt, solvate or prodrug
thereof, ##STR59## wherein A is heteroaryl; m is 0, 1 or 2; n is 0,
1, 2, 3 or 4; and n+m>0; each R.sup.1 is independently selected
from OH, --(CH.sub.2).sub.1-4OH, --CH.sub.3-aF.sub.a,
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a, --OCH.sub.3-aF.sub.a, halo,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2,
NH.sub.2, --NH--C.sub.1-4alkyl, --N-di-(C.sub.1-4alkyl), CN,
formyl, phenyl and heterocyclyl optionally substituted with
C.sub.1-6alkyl; each R.sup.2 is the group Y--X--; each X and
X.sup.1 is a linker independently selected from -Z-, --O-Z-,
--O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-,
--N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-, --SO.sub.2N(R.sup.7)-Z-,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-, --C.ident.C-Z-,
--N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each Y is
independently selected from aryl-Z.sup.1-, heterocyclyl-Z.sup.1-,
C.sub.3-7cycloalkyl-Z.sup.1-, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a and
--CH(OH)CH.sub.3-aF.sub.a; wherein each Y is independently
optionally substituted with up to 3 R.sup.4 groups; each R.sup.4 is
independently selected from halo, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH,
--C(O)OC.sub.1-6alkyl, OH, phenyl optionally substituted with
C.sub.1-6alkyl or --C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--;
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, phenyl, naphthyl, heterocyclyl and
C.sub.3-7cycloalkyl; wherein R.sup.5 is optionally substituted with
halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
COOH, or --C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl
or heterocyclyl ring in R.sup.5 is optionally substituted with
halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; each Z.sup.1
is independently selected from a direct bond, C.sub.2-6alkenylene
and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; R.sup.3
is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6; R.sup.6 is
selected from hydrogen, C.sub.1-6alkyl, --OC.sub.1-6alkyl,
SO.sub.2C.sub.1-6alkyl, and (CH.sub.2).sub.0-3OH; each R.sup.7 is
independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each a is independently 1, 2 or
3; p is 0, 1 or 2; q is 0, 1 or 2; and p+q<4; with the proviso
that: (i) when m is 1 or 2 and n is 0, R.sup.3 is OH or
--O--C.sub.1-6alkyl, then R.sup.1 is other than OH, CN, halo,
methyl, amino or nitro; (ii) when m is 0, n is 1, X is --O--,
--O--C(O)--, --S--, --S(O)--, --S(O.sub.2)--, --N(CH.sub.3)--,
--N(CH.sub.3)--CH.sub.2-- or --C(O)--NH--, R.sup.3 is OH or
--O--C.sub.1-6alkyl, then Y cannot be C.sub.1-6alkyl or
C.sub.1-6alkyl substituted with C.sub.1-6alkyl; (iii) when m is 0
or 1 and R.sup.1 is NO.sub.2, R.sup.3 is OH or --O--C.sub.1-6alkyl,
then when n is 2, (R.sup.2), cannot be di-C.sub.1-6alkyl-O-- or
C.sub.1-6alkyl-O--C.sub.1-6alkenyl-O-- and when n is 3, (R.sup.2),
cannot be tri-C.sub.1-6alkyl-O--; (iv) when A is pyridyl, m is 0 or
1 and R.sup.1 is halo, n is 1 and R.sup.2 is phenyl,
phenyl-CH.sub.2--O-- or pyridyl-NH--, then R.sup.3 cannot be OH or
--O--C.sub.1-6alkyl; and (v) when A is pyridyl, R.sup.3 is OH, m is
0, n is 2 and one of the R.sup.2 groups is phenyl-CH.sub.2--O--,
then the other R.sup.2 group must be other than CH.sub.3--S-- or
CH.sub.3--SO.sub.2--.
22. A compound according to claim 21 or a salt, solvate or prodrug
thereof, wherein m is 0 or 1 and n is 1 or 2.
23. A compound according to claim 22 or a salt, solvate or prodrug
thereof, wherein n+m is 2 and the R.sup.1 and/or R.sup.2 groups are
substitutents at the 2- and 5-positions.
24. A compound according to claim 21 or a salt, solvate or prodrug
thereof, wherein each R.sup.1 is independently selected from OH,
CH.sub.3-aF.sub.a, OCH.sub.3-aF.sub.a, halo, C.sub.1-6alkyl,
NO.sub.2 and heterocyclyl optionally substituted with
C.sub.1-6alkyl.
25. A compound according to claim 21 or a salt, solvate or prodrug
thereof, wherein each R.sup.2 is the group Y--X--; each X is
independently selected from --O-Z-, --C(O)O-Z-, --S-Z-, --SO-Z-,
--SO.sub.2-Z-, --N(R.sup.7)SO.sub.2, Z-SO.sub.2NH-Z-,
--(CH.sub.2).sub.1 4-, --CH.dbd.CH-Z-, --C.ident.C-Z-,
--N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z- and a direct bond; and each
Y is independently selected from aryl-Z.sup.1-,
heterocyclyl-Z.sup.1-, C.sub.3-7 cycloalkyl-Z.sup.1-, C.sub.1-6
alkyl, C.sub.2-6alkenyl and --CH(OH)CH.sub.3-aF.sub.a; wherein each
Y is independently optionally substituted with R.sup.4.
26. A compound according to claim 21 or a salt, solvate or prodrug
thereof, wherein each R.sup.4 is independently selected from halo,
--CH.sub.3-aF.sub.a, --OCH.sub.3-aF.sub.a, CN, NO.sub.2,
C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH,
--(CH.sub.2).sub.1-3COOH, --(CH.sub.2).sub.0-3COOH, --C(O)phenyl,
--C(O)NH.sub.2, --C(O)NH-phenyl, --SO.sub.2NH.sub.2,
--SO.sub.2C.sub.1-6alkyl, and phenyl optionally substituted with
C.sub.1-6alkyl or --C(O)OC.sub.1-6alkyl.
27. A compound of Formula (II) or a salt, solvate or prodrug
thereof, ##STR60## wherein A is heteroaryl, except A is not
pyridyl; each X and X.sup.1 is a linker independently selected from
-Z-, --O-Z-, --O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-, --SO-Z-,
--SO.sub.2-Z-, --N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-,
--SO.sub.2N(R.sup.7)-Z-, --(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-,
--C.ident.C-Z-, --N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each
R.sup.7 is independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each Z.sup.1 is independently
selected from a direct bond, C.sub.2-6alkenylene and a group of the
formula --(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--;
R.sup.3 is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6;
R.sup.6 is selected from hydrogen, C.sub.1-6alkyl, OC.sub.1-6alkyl,
SO.sub.2C.sub.1-6alkyl, and (CH.sub.2).sub.0-3OH; each R.sup.4 is
independently selected from halo, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH,
--C(O)OC.sub.1-6alkyl, OH, phenyl optionally substituted with
C.sub.1-6alkyl or --C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--;
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, phenyl, naphthyl, heterocyclyl and
C.sub.3-7cycloalkyl; wherein R.sup.5 is optionally substituted with
halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
COOH, or --C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl
or heterocyclyl ring in R.sup.5 is optionally substituted with
halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; each a is
independently 1, 2 or 3; p is 0, 1 or 2; q is 0, 1 or 2; and
p+q<4.
28. A compound of Formula (IIa) or a salt, solvate or prodrug
thereof, ##STR61## wherein Het is a monocyclic heterocyclyl,
optionally substituted with between 1 and 3 groups selected from
R.sup.4; each R.sup.4 is independently selected from halo,
--CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, --COOH, --C(O)OC.sub.1-6alkyl, OH, phenyl
optionally substituted with C.sub.1-6alkyl or
--C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--; R.sup.5 is selected
from hydrogen, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, phenyl,
naphthyl, heterocyclyl and C.sub.3-7cycloalkyl; wherein R.sup.5 is
optionally substituted with halo, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, COOH, or
--C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl or
heterocyclyl ring in R.sup.5 is optionally substituted with halo,
CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; A is
heteroaryl; each X and X.sup.1 is a linker independently selected
from -Z-, --O-Z-, --O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-,
--SO-Z-, --SO.sub.2-Z-, --N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-,
--SO.sub.2N(R.sup.7)-Z-, --(CH.sub.2).sub.14--, --CH.dbd.CH-Z-,
--C.ident.C-Z-, --N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each
R.sup.7 is independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each Z.sup.1 is independently
selected from a direct bond, C.sub.2-6alkenylene and a group of the
formula --(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--;
R.sup.3 is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6;
R.sup.6 is selected from hydrogen, C.sub.1-6alkyl, OC.sub.1-6alkyl,
SO.sub.2C.sub.1-6alkyl, and (CH.sub.2).sub.0-3OH; each a is
independently 1, 2 or 3; p is 0, 1 or 2; q is 0, 1 or 2; and
p+q<4.
29. A compound of Formula (IIf) or a salt, solvate or pro-drug
thereof, ##STR62## wherein Het is a monocyclic heterocyclyl;
wherein the Het and C.sub.1-6alkyl groups are independently
optionally substituted with between 1 and 3 groups selected from
R.sup.4, and wherein the C.sub.1-6alkyl group optionally contains a
double bond; each R.sup.4 is independently selected from halo,
--CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, --COOH, --C(O)OC.sub.1-6alkyl, OH, phenyl
optionally substituted with C.sub.1-6alkyl or
--C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--; R.sup.5 is selected
from hydrogen, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, phenyl,
naphthyl, heterocyclyl and C.sub.3-7cycloalkyl; wherein R.sup.5 is
optionally substituted with halo, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, COOH, or
--C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl or
heterocyclyl ring in R.sup.5 is optionally substituted with halo,
CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; A is
heteroaryl; each X and X.sup.1 is a linker independently selected
from -Z-, --O-Z-, --O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-,
--SO-Z-, --SO.sub.2-Z-, --N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-,
--SO.sub.2N(R.sup.7)-Z-, --(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-,
--C.ident.C-Z-, --N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each
R.sup.7 is independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each Z.sup.1 is independently
selected from a direct bond, C.sub.2-6alkenylene and a group of the
formula --(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--;
R.sup.3 is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6;
R.sup.6 is selected from hydrogen, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, SO.sub.2C.sub.1-6alkyl, and
(CH.sub.2).sub.0-3OH; each a is independently 1, 2 or 3; p is an
integer between 0 and 2; q is an integer between 0 and 2; and
p+q<4.
30. A compound according to claim 27, or a salt, solvate or prodrug
thereof, wherein X is independently selected from --O-Z-,
SO.sub.2N(R.sup.7)-Z- and --N(R.sup.7)-Z-; Z is independently
selected from a direct bond and --CH.sub.2--; and Z.sup.1 is
independently selected from a direct bond, --CH.sub.2--,
--(CH.sub.2).sub.2-- and ##STR63##
31. A compound according to claim 21 or a salt, solvate or prodrug
thereof, wherein A is selected from pyridyl, pyrimidinyl,
pyrazinyl, furanyl and thiazolyl.
32. A process for the preparation of a compound of Formula (I), or
a salt, solvate or prodrug thereof, ##STR64## wherein A is
heteroaryl; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; and n+m>0;
each R.sup.1 is independently selected from OH,
--(CH.sub.2).sub.1-4OH, --CH.sub.3-aF.sub.a,
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a, --OCH.sub.3-aF.sub.a, halo,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2,
NH.sub.2, --NH--C.sub.1-4alkyl, --N-di-(C.sub.1-4alkyl), CN,
formyl, phenyl and heterocyclyl optionally substituted with
C.sub.1-6alkyl; each R.sup.2 is the group Y--X--; each X and
X.sup.1 is a linker independently selected from -Z-, --O-Z-,
--O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-,
--N(R.sup.7)-Z-, --N(R.sup.7)SO.sub.2-Z-, --SO.sub.2N(R.sup.7)-Z-,
--(CH.sub.2).sub.14--, --CH.dbd.CH-Z-, --C.ident.C-Z-,
--N(R.sup.7)CO-Z-, --C(O)N(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- and a direct bond; each Z is independently selected from
a direct bond, C.sub.2-6alkenylene and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; each Y is
independently selected from aryl-Z.sup.1-, heterocyclyl-Z.sup.1-,
C.sub.3-7cycloalkyl-Z.sup.1-, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a and
--CH(OH)CH.sub.3-aF.sub.a; wherein each Y is independently
optionally substituted with up to 3 R.sup.4 groups; each R.sup.4 is
independently selected from halo, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH,
--C(O)OC.sub.1-6alkyl, OH, phenyl optionally substituted with
C.sub.1-6alkyl or --C(O)OC.sub.1-6alkyl, and R.sup.5--X.sup.1--;
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl,
--CH.sub.3-aF.sub.a, phenyl, naphthyl, heterocyclyl and
C.sub.3-7cycloalkyl; wherein R.sup.5 is optionally substituted with
halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
COOH, or --C(O)OC.sub.1-6alkyl, and wherein each phenyl, naphthyl
or heterocyclyl ring in R.sup.5 is optionally substituted with
halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; each Z.sup.1
is independently selected from a direct bond, C.sub.2-6alkenylene
and a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; R.sup.3
is selected from OH, --OC.sub.1-6alkyl and NHR.sup.6; R.sup.6 is
selected from hydrogen, C.sub.1-6alkyl, --OC.sub.1-6alkyl,
--SO.sub.2C.sub.1-6alkyl, and --(CH.sub.2).sub.0-3OH; each R.sup.7
is independently selected from hydrogen, C.sub.1-6alkyl and
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; each a is independently 1, 2 or
3; p is 0, 1 or 2; q is 0, 1 or 2; and p+q<4; which comprises
(a) reacting a compound of Formula (IIIa) with a compound of
Formula (IIIb), ##STR65## (b) for compounds of Formula (I) wherein
R.sup.3 is hydrogen, de-protecting a compound of Formula (IIIc),
##STR66## wherein P.sup.1 is a protecting group; (c) reacting a
compound of Formula (IIId) with a compound of Formula (IIIe),
##STR67## wherein X' and X'' comprise groups which when reacted
together form the group X; (d) for a compound of Formula (I)
wherein X or X.sup.1 is --SO-Z- or --SO.sub.2-Z-, oxidizing the
corresponding compound of Formula (I) wherein X or X.sup.1
respectively is --S-Z-; or (e) for a compound of Formula (I)
wherein R.sup.3 is NHR.sup.6, reacting a compound of Formula (IIIf)
with a compound of Formula (IIIg), ##STR68## and optionally: i)
converting a compound of Formula (I) into another compound of
Formula (I); ii) removing any protecting groups; and/or iii)
forming a salt, pro-drug or solvate thereof.
33. A method for the combined treatment or prevention of diabetes
and obesity comprising administering a GLK activator.
34. A method for the combined treatment or prevention of diabetes
and obesity comprising administering a GLK activator selected from
a compound of Formula Ib, II, IIa or IIf, according to any one of
claims 21 to 31, or a salt, solvate or prodrug thereof.
35. A pharmaceutical composition comprising a compound of Formula
Ib, II, IIa or IIf, according to any one of claims 21 to 31, or a
salt, solvate or prodrug thereof with a pharmaceutically acceptable
diluent or carrier.
Description
[0001] The present invention relates to compounds which activate
glucokinase (GLK), leading to a decreased glucose threshold for
insulin secretion. In addition the compounds are predicted to lower
blood glucose by increasing hepatic glucose uptake. Such compounds
may have utility in the treatment of Type 2 diabetes and obesity.
The invention also relates to pharmaceutical compositions
comprising a compound of the invention, and use of such a compound
in the conditions described above.
[0002] In the pancreatic .beta.-cell and liver parenchymal cells
the main plasma membrane glucose transporter is GLUT2. Under
physiological glucose concentrations the rate at which GLUT2
transports glucose across the membrane is not rate limiting to the
overall rate of glucose uptake in these cells. The rate of glucose
uptake is limited by the rate of phosphorylation of glucose to
glucose-6-phosphate (G-6-P) which is catalysed by glucokinase (GLK)
[1]. GLK has a high (6-10 mM) Km for glucose and is not inhibited
by physiological concentrations of G-6-P [1]. GLK expression is
limited to a few tissues and cell types, most notably pancreatic
.beta.-cells and liver cells (hepatocytes) [1]. In these cells GLK
activity is rate limiting for glucose utilisation and therefore
regulates the extent of glucose induced insulin secretion and
hepatic glycogen synthesis. These processes are critical in the
maintenance of whole body glucose homeostasis and both are
dysfunctional in diabetes [2].
[0003] In one sub-type of diabetes, Type 2 maturity-onset diabetes
of the young (MODY-2), the diabetes is caused by GLK loss of
function mutations [3, 4]. Hyperglycaemia in MODY-2 patients
results from defective glucose utilisation in both the pancreas and
liver [5]. Defective glucose utilisation in the pancreas of MODY-2
patients results in a raised threshold for glucose stimulated
insulin secretion. Conversely, rare activating mutations of GLK
reduce this threshold resulting in familial hyperinsulinism [6, 7].
In addition to the reduced GLK activity observed in MODY-2
diabetics, hepatic glucokinase activity is also decreased in type 2
diabetics [8]. Importantly, global or liver selective
overexpression of GLK prevents or reverses the development of the
diabetic phenotype in both dietary and genetic models of the
disease [9-12]. Moreover, acute treatment of type 2 diabetics with
fructose improves glucose tolerance through stimulation of hepatic
glucose utilisation [13]. This effect is believed to be mediated
through a fructose induced increase in cytosolic GLK activity in
the hepatocyte by the mechanism described below [13].
[0004] Hepatic GLK activity is inhibited through association with
GLK regulatory protein (GLKRP). The GLK/GLKRP complex is stabilised
by fructose-6-phosphate (F6P) binding to the GLKRP and destabilised
by displacement of this sugar phosphate by fructose-1-phosphate
(F1P). F1P is generated by fructokinase mediated phosphorylation of
dietary fructose. Consequently, GLK/GLKRP complex integrity and
hepatic GLK activity is regulated in a nutritionally dependent
manner as F6P is elevated in the post-absorptive state whereas F1P
predominates in the post-prandial state. In contrast to the
hepatocyte, the pancreatic D-cell expresses GLK in the absence of
GLKRP. Therefore, 13-cell GLK activity is regulated exclusively by
the availability of its substrate, glucose. Small molecules may
activate GLK either directly or through destabilising the GLK/GLKRP
complex. The former class of compounds are predicted to stimulate
glucose utilisation in both the liver and the pancreas whereas the
latter are predicted to act exclusively in the liver. However,
compounds with either profile are predicted to be of therapeutic
benefit in treating Type 2 diabetes as this disease is
characterised by defective glucose utilisation in both tissues.
[0005] In WO0058293 and WO 01/44216 (Roche), a series of
benzylcarbamoyl compounds are described as glucokinase activators.
The mechanism by which such compounds activate GLK is assessed by
measuring the direct effect of such compounds in an assay in which
GLK activity is linked to NADH production, which in turn is
measured optically--see details of the in vitro assay described in
Example A.
[0006] In WO9622282/93/94/95 and WO9749707/8 are disclosed a number
of intermediates used in the preparation of compounds useful as
vasopressin agents which are related to those disclosed in the
present invention. Related compounds are also disclosed in
WO9641795 and JP8143565 (vasopressin antagonism), in JP8301760
(skin damage prevention) and in EP619116 (osteopathy).
[0007] We present as a feature of the invention the use of a
compound of Formula (I) or a salt, pro-drug or solvate thereof, in
the preparation of a medicament for use in the treatment or
prevention of a disease or medical condition mediated through GLK:
##STR1## wherein [0008] A is heteroaryl; [0009] m is 0, 1 or 2;
[0010] n is 0, 1, 2, 3 or 4; [0011] and n+m>0; [0012] each
R.sup.1 is independently selected from OH, --(CH.sub.2).sub.1-4OH,
--CH.sub.3-aF.sub.a, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a,
--OCH.sub.3-aF.sub.a, halo, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, NO.sub.2, NH.sub.2, --NH--C.sub.1-4alkyl,
--N-di-(C.sub.1-4alkyl), CN, formyl, phenyl or heterocyclyl
optionally substituted by C.sub.1-6alkyl; [0013] each R.sup.2 is
the group Y--X-- [0014] wherein each X is a linker independently
selected from: [0015] -Z-, --O-Z-, --O-Z-O-z-, --C(O)O-Z-,
--OC(O)-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-, --N(R.sup.7)-Z-,
--N(R.sup.7)SO.sub.2-Z-, --SO.sub.2N(R.sup.7)-Z-,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-, --C.ident.C-Z-,
--N(R.sup.7)CO-Z-, --CON(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- or a direct bond; [0016] each Z is independently a direct
bond, C.sub.2-6alkenylene or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; [0017]
each Y is independently selected from aryl-Z.sup.1-,
heterocyclyl-Z.sup.1-, C.sub.3-7cycloalkyl-Z.sup.1-,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl,
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a or --CH(OH)CH.sub.3-aF.sub.a;
wherein [0018] each Y is independently optionally substituted by up
to 3 R.sup.4 groups; [0019] each R.sup.4 is independently selected
from halo, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH, --C(O)OC.sub.1-6alkyl,
OH or phenyl optionally substituted by C.sub.1-6alkyl or
--C(O)OC.sub.1-6alkyl, or R.sup.5--X.sup.1--, where X.sup.1 is
independently as defined in X above and R.sup.5 is selected from
hydrogen, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, phenyl, naphthyl,
heterocyclyl or C.sub.3-7cycloalkyl; and R.sup.5 is optionally
substituted by halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, COOH, or --C(O)OC.sub.1-6alkyl, [0020] wherein
each phenyl, naphthyl or heterocyclyl ring in R.sup.5 is optionally
substituted by halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
C.sub.1-6alkyl, --OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or
OH; [0021] each Z.sup.1 is independently a direct bond,
C.sub.2-6alkenylene or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; [0022]
R.sup.3 is selected from OH, --O--C.sub.1-6alkyl or NHR.sup.6;
[0023] R.sup.6 is selected from hydrogen, C.sub.1-6alkyl,
--O--C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl,
--(CH.sub.2).sub.0-3OH; [0024] R.sup.7 is independently selected
from hydrogen, C.sub.1-6alkyl or
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; [0025] each a is independently
1, 2 or 3; [0026] p is an integer between 0 and 2; [0027] q is an
integer between 0 and 2; [0028] and p+q<4.
[0029] According to a further feature of the invention there is
provided the use of a compound of Formula (Ia) or a salt, pro-drug
or solvate thereof, in the preparation of a medicament for use in
the treatment or prevention of a disease or medical condition
mediated through GLK: ##STR2## wherein [0030] m is 0, 1 or 2;
[0031] n is 0, 1, 2, 3 or 4; [0032] and n+m>0; [0033] each
R.sup.1 is independently selected from OH, (CH.sub.2).sub.1-4OH,
CH.sub.3-aF.sub.a, (CH.sub.2).sub.1-4CH.sub.3-aF.sub.a,
OCH.sub.3-aF.sub.a, halo, C.sub.1-6 alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, NO.sub.2, NH.sub.2, CN, phenyl or a heterocyclyl
optionally substituted by C.sub.1-6alkyl; [0034] each R.sup.2 is
the group Y--X-- [0035] wherein each X is a linker independently
selected from [0036] --O(CH.sub.2).sub.0-3--,
--(CH.sub.2).sub.0-3O--, --C(O)O(CH.sub.2).sub.0-3--,
--S(CH.sub.2).sub.0-3--, --SO(CH.sub.2).sub.0-3--,
--SO.sub.2(CH.sub.2).sub.0-3--, --NHSO.sub.2, --SO.sub.2NH--,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH(CH.sub.2).sub.0-2--,
--C.ident.C(CH.sub.2).sub.0-2--, --NHCO--, --CONH--; [0037] each Y
is independently selected from phenyl(CH.sub.2).sub.0-2,
naphthyl(CH.sub.2).sub.0-2, heterocyclyl(CH.sub.2).sub.0-2,
C.sub.3-7 cycloalkyl(CH.sub.2).sub.0-2, C.sub.1-6 alkyl,
OC.sub.1-6alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, or
CH(OH)CH.sub.3-aF.sub.a; wherein each Y is independently optionally
substituted by one or more R.sup.4 groups; [0038] each R.sup.4 is
independently selected from halo, CH.sub.3-aF.sub.a,
OCH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
OC.sub.1-6alkyl, COOH, (CH.sub.2).sub.0-3COOH,
O(CH.sub.2).sub.0-3COOH, C(O)OC.sub.1-6alkyl,
C.sub.1-6alkylC(O)OC.sub.1-6alkyl, CO-phenyl, CONH.sub.2,
CONH-phenyl, SO.sub.2NH.sub.2, SO.sub.2C.sub.1-6alkyl, OH, or
phenyl optionally substituted by one or more R.sup.5 groups where
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl or
C(O)OC.sub.1-6alkyl. [0039] each a is independently 1, 2 or 3;
[0040] R.sup.3 is selected from hydrogen, C.sub.1-6alkyl or
NHR.sup.6; [0041] R.sup.6 is selected from hydrogen,
C.sub.1-6alkyl, OC.sub.1-6alkyl, SO.sub.2C.sub.1-6alkyl,
(CH.sub.2).sub.0-3OH.
[0042] According to a further feature of the invention there is
provide a compound of Formula (Ib) or a salt, solvate or pro-drug
thereof; ##STR3## wherein [0043] A is heteroaryl; [0044] m is 0, 1
or 2; [0045] n is 0, 1, 2, 3 or 4; [0046] and n+m>0; [0047] each
R.sup.1 is independently selected from OH, --(CH.sub.2).sub.1-4OH,
--CH.sub.3-aF.sub.a, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a,
--OCH.sub.3-aF.sub.a, halo, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-4alkynyl, NO.sub.2, NH.sub.2, --NH--C.sub.1-4alkyl,
--N-di-(C.sub.1-4alkyl), CN, formyl, phenyl or heterocyclyl
optionally substituted by C.sub.1-6alkyl; [0048] each R.sup.2 is
the group Y--X-- [0049] wherein each X is a linker independently
selected from: [0050] -Z-, --O-Z-, --O-Z-O-Z-, --C(O)O-Z-,
--OC(O)-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-, --N(R.sup.7)-Z-,
--N(R.sup.7)SO.sub.2-Z-, --SO.sub.2N(R.sup.7)-Z-,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-, --C.ident.C-Z-,
--N(R.sup.7)CO-Z-, --CON(R.sup.7)-Z-,
--C(O)N(R.sup.7)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.7)C(O)-Z-,
--C(O)-Z- or a direct bond; [0051] each Z is independently a direct
bond, C.sub.2-6alkenylene or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.7).sub.2--(CH.sub.2).sub.q--; [0052]
each Y is independently selected from aryl-Z.sup.1-,
heterocyclyl-Z.sup.1-, C.sub.3-7cycloalkyl-Z.sup.1-,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl,
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a or --CH(OH)CH.sub.3-aF.sub.a;
wherein [0053] each Y is independently optionally substituted by up
to 3 R.sup.4 groups; [0054] each R.sup.4 is independently selected
from halo, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
C.sub.1-6alkyl, --OC.sub.1-6alkyl, --COOH, --C(O)OC.sub.1-6alkyl,
OH or phenyl optionally substituted by C.sub.1-6alkyl or
--C(O)OC.sub.1-6alkyl, [0055] or R.sup.5--X.sup.1--, where X.sup.1
is independently as defined in X above and R.sup.5 is selected from
hydrogen, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, phenyl, naphthyl,
heterocyclyl or C.sub.3-7cycloalkyl; and R.sup.5 is optionally
substituted by halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN,
NO.sub.2, NH.sub.2, COOH, or --C(O)OC.sub.1-6alkyl, [0056] wherein
each phenyl, naphthyl or heterocyclyl ring in R.sup.5 is optionally
substituted by halo, CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
C.sub.1-6alkyl, --OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or
OH; [0057] each Z.sup.1 is independently a direct bond,
C.sub.2-6alkenylene or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; [0058]
R.sup.3 is selected from OH, --O--C.sub.1-6alkyl or NHR.sup.6;
[0059] R.sup.6 is selected from hydrogen, C.sub.1-6alkyl,
--O--C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl,
--(CH.sub.2).sub.0-3OH; [0060] R.sup.7 is independently selected
from hydrogen, C.sub.1-6alkyl or
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; [0061] each a is independently
1, 2 or 3; [0062] p is an integer between 0 and 2; [0063] q is an
integer between 0 and 2; [0064] and p+q<4. with the proviso
that: [0065] (i) when m is 1 or 2 and n is 0, R.sup.3 is OH or
--C.sub.1-6alkyl, then R.sup.1 is other than OH, CN, halo, methyl,
amino or nitro; [0066] (ii) when m=0, n=1, X is --O--, --O--C(O)--,
--S--, --S(O)--, --S(O.sub.2)--, --N(CH.sub.3)--,
--N(CH.sub.3)--CH.sub.2-- or --C(O)--NH--, R.sup.3 is OH or
--O--C.sub.1-6alkyl, then Y cannot be C.sub.1-6alkyl or
C.sub.1-6alkyl substituted by C.sub.1-6alkyl; [0067] (iii) when m
is 0 or m is 1 and R.sup.1 is NO.sub.2, R.sup.3 is OH or
--O--C.sub.1-6alkyl, then when n is 2 (R.sup.2).sub.n cannot be
di-C.sub.1-6alkyl-O-- or C.sub.1-6alkyl-O--C.sub.1-6alkenyl-O-- and
when n is 3 (R.sup.2), cannot be tri-C.sub.1-6alkyl-O--; [0068]
(iv) when A is pyridyl, m is 0 or m is 1 and R.sup.1 is halo, n is
1 and R.sup.2 is phenyl, phenyl-CH.sub.2--O-- or pyridyl-NH--, then
R.sup.3 cannot be OH or --O--C.sub.1-6alkyl; and [0069] (v) when A
is pyridyl, R.sup.3 is OH, m is 0, n is 2 and one of the R.sup.2
groups is phenyl-CH.sub.2--O--, then the other R.sup.2 group must
be other than CH.sub.3--S-- or CH.sub.3--SO.sub.2--.
[0070] According to a further feature of the invention there is
provided a compound of Formula (Ib) or salt, solvate of pro-drug
thereof,
wherein A is pyridyl
with the proviso that:
[0071] (i) when m is 1 or 2 and n is 0 then R.sup.1 is other than
halo, methyl, amino or nitro; [0072] (ii) when m=0, n=1, X is
--O--, --S--, --S(O)--, --S(O.sub.2)--, --N(CH.sub.3)--, or
--N(CH.sub.3)--CH.sub.2--, R.sup.3 is OH or --C.sub.1-6alkyl, then
Y cannot be methyl; [0073] (iii) when R.sup.3 is OH, m is 0, n is 2
and one of the R.sup.2 groups is phenyl-CH.sub.2--O--, then the
other R.sup.2 group must be other than CH.sub.3--S-- or
CH.sub.3--SO.sub.2--; and [0074] (iv) when m is 0 or m is 1 and
R.sup.1 is halo, n is 1 and R.sup.2 is phenyl, phenyl-CH.sub.2--O--
or pyridyl-NH--, then R.sup.3 cannot be OH or
--O--C.sub.1-6alkyl.
[0075] According to a further feature of the invention there is
provided a compound of Formula (Ic) or a salt, solvate or pro-drug
thereof; ##STR4## wherein [0076] m is 0, 1 or 2; [0077] n is 0, 1,
2, 3 or 4; [0078] and n+m>0; [0079] each R.sup.1 is
independently selected from OH, (CH.sub.2).sub.1-4OH,
CH.sub.3-aF.sub.a, (CH.sub.2).sub.1-4CH.sub.3-aF.sub.a,
OCH.sub.3-aF.sub.a, halo, C.sub.1-6 alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, NO.sub.2, NH.sub.2, CN, phenyl or a heterocyclyl
optionally substituted by C.sub.1-6alkyl; [0080] each R.sup.2 is
the group Y--X-- [0081] wherein each X is a linker independently
selected from [0082] --O(CH.sub.2).sub.0-3--,
--(CH.sub.2).sub.0-3O--, --C(O)O(CH.sub.2).sub.0-3--,
--S(CH.sub.2).sub.0-3--, --SO(CH.sub.2).sub.0-3--,
--SO.sub.2(CH.sub.2).sub.0-3--, --NHSO.sub.2, --SO.sub.2NH--,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH(CH.sub.2).sub.0-2--,
--C.ident.C(CH.sub.2).sub.0-2--, --NHCO--, --CONH--; [0083] each Y
is independently selected from phenyl(CH.sub.2).sub.0-2,
naphthyl(CH.sub.2).sub.0-2, heterocyclyl(CH.sub.2).sub.0-2,
C.sub.3-7 cycloalkyl(CH.sub.2).sub.0-2, C.sub.1-6 alkyl,
OC.sub.1-6alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, or
CH(OH)CH.sub.3-aF.sub.a; wherein each Y is independently optionally
substituted by one or more R.sup.4 groups; [0084] each R.sup.4 is
independently selected from halo, CH.sub.3-aF.sub.a,
OCH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
OC.sub.1-6alkyl, COOH, (CH.sub.2).sub.0-3COOH,
O(CH.sub.2).sub.0-3COOH, C(O)OC.sub.1-6alkyl,
C.sub.1-6alkylC(O)OC.sub.1-6alkyl, CO-phenyl, CONH.sub.2,
CONH-phenyl, SO.sub.2NH.sub.2, SO.sub.2C.sub.1-6alkyl, OH, or
phenyl optionally substituted by one or more R.sup.5 groups where
R.sup.5 is selected from hydrogen, C.sub.1-6alkyl or
C(O)OC.sub.1-6alkyl. [0085] each a is independently 1, 2 or 3;
[0086] R.sup.3 is selected from hydrogen, C.sub.1-6alkyl or
NHR.sup.6; [0087] R.sup.6 is selected from hydrogen,
C.sub.1-6alkyl, OC.sub.1-6alkyl, SO.sub.2C.sub.1-6alkyl,
(CH.sub.2).sub.0-3OH; with the proviso that: [0088] (i) when
R.sup.3 is H, m is 0, n is 2 and one of the R.sup.2 groups is
phenyl-CH.sub.2--O--, then the other R.sup.2 group must be other
than CH.sub.3--S-- or CH.sub.3--SO.sub.2--; and [0089] (ii) when
R.sup.3 is H, m is 1, n is 1 and R.sup.2 is phenyl-CH.sub.2--O--,
then R.sup.1 must be other than halo.
[0090] Compounds of the invention may form salts which are within
the ambit of the invention. Pharmaceutically acceptable salts are
preferred although other salts may be useful in, for example,
isolating or purifying compounds.
[0091] The term "aryl" refers to phenyl, naphthyl or a partially
saturated bicyclic carbocyclic ring containing between 8 and 12
carbon atoms, preferably between 8 and 10 carbon atoms. Example of
partially saturated bicyclic carbocyclic ring include:
1,2,3,4-tetrahydronaphthyl, indanyl, indenyl,
1,2,4a,5,8,8a-hexahydronaphthyyl or 1,3a-dihydropentalene.
[0092] The term "halo" includes fluoro, chloro, bromo and iodo;
preferably chloro, bromo and fluoro; most preferably fluoro.
[0093] The expression "--CH.sub.3-aF.sub.a" wherein a is an integer
between 1 and 3 refers to a methyl group in which 1, 2 or all 3
hydrogen are replaced by a fluorine atom. Examples include:
trifluoromethyl, difluoromethyl and fluoromethylene An analogous
notation is used with reference to the group
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a, examples include:
2,2-difluoroethyl and 3,3,3-trifluoropropyl.
[0094] In this specification the term "alkyl" includes both
straight and branched chain alkyl groups. For example,
"C.sub.1-4alkyl" includes propyl, isopropyl and tert-butyl.
[0095] The term "heteroaryl" refers to a monocylic aromatic
heterocyclic ring containing between 5-6 atoms of which at least
one atom is chosen from nitrogen, sulphur or oxygen, which may,
unless otherwise specified, be carbon or nitrogen linked, wherein a
--CH.sub.2-- group can optionally be replaced by a --C(O)-- and
sulphur atoms in a heterocyclic ring may be oxidised to S(O) or
S(O).sub.2 groups. Examples of "heteroaryl" include: thiazolidinyl,
pyrrolidinyl, pyrrolinyl, 2-oxopyrrolidinyl, 2,5-dioxopyrrolidinyl,
1,1-dioxotetrahydrothienyl, 2,4-dioxoimidazolidinyl,
2-oxo-1,3,4-(4-triazolinyl), 2-oxo-oxazolidininyl,
5,6-dihydrouracilyl, 1,2,4-oxadiazolyl, 4-oxothiazolidinyl,
morpholinyl, furanyl, 2-oxotetrahydrofuranyl, tetrahydrofuranyl,
thienyl, isoxazolyl, tetrahydropyranyl, piperidyl, piperazinyl,
thiomorpholinyl, 1,1-dioxothiomorpholinyl, tetrahydropyranyl,
1,3-dioxolanyl, homopiperazinyl, isoxazolyl, imidazolyl, pyrrolyl,
thiazolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl,
1,2,3-triazolyl, pyranyl, pyrimidyl, pyrazinyl, pyridazinyl,
pyridyl, 4-oxo-pyridinyl, 1,1-dioxotetrahydrothienyl. Preferably
"heteroaryl" is selected from: pyridyl, pyrimidinyl, pyrazinyl,
furanyl or thiazolyl.
[0096] The term "heterocyclyl" is a saturated, partially saturated
or unsaturated, mono or bicyclic ring containing 3-12 atoms of
which at least one atom is chosen from nitrogen, sulphur or oxygen,
which may, unless otherwise specified, be carbon or nitrogen
linked, wherein a --CH.sub.2-- group can optionally be replaced by
a --C(O)-- and sulphur atoms in a heterocyclic ring may be oxidised
to S(O) or S(O).sub.2 groups. Preferably a "heterocyclyl" is a
saturated, partially saturated or unsaturated, mono or bicyclic
ring (preferably monocyclic) containing 5 or 6 atoms of which 1 to
3 atoms are nitrogen, sulphur or oxygen, which may, unless
otherwise specified, be carbon or nitrogen linked, wherein a
--CH.sub.2-- group can optionally be replaced by a --C(O)-- or
sulphur atoms in a heterocyclic ring may be oxidised to S(O) or
S(O).sub.2 groups. Examples and suitable values of the term
"heterocyclyl" are thiazolidinyl, pyrrolidinyl, pyrrolinyl,
2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl,
1,1-dioxotetrahydrothienyl, 2,4-dioxoimidazolidinyl,
2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydrouracilyl,
1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl,
4-thiazolidonyl, morpholino, furanyl, 2-oxotetrahydrofuranyl,
tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl,
isoxazolyl, tetrahydropyranyl, piperidyl,
1-oxo-1,3-dihydroisoindolyl, piperazinyl, thiomorpholino,
1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl,
homopiperazinyl, thienyl, isoxazolyl, imidazolyl, pyrrolyl,
thiazolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl,
1,2,3-triazolyl, pyranyl, indolyl, pyrimidyl, pyrazinyl,
pyridazinyl, pyridyl, 4-pyridonyl, quinolyl, tetrahydrothienyl
1,1-dioxide, 2-oxo-pyrrolidinyl and 1-isoquinolonyl. Preferred
examples of "heterocyclyl" when referring to a 5/6 and 6/6 bicyclic
ring system include benzofuranyl, benzimidazolyl, benzthiophenyl,
benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl,
pyridoimidazolyl, pyrimidoimidazolyl, quinolinyl, isoquinolinyl,
quinoxalinyl, quinazolinyl, phthalazinyl, cinnolinyl,
imidazo[2,1-b][1,3]thiazolyl, chromanyl and naphthyridinyl.
Preferably the term "heterocyclyl" refers to 5- or 6-membered
monocyclic heterocyclic rings, such as oxazolyl, isoxazolyl,
pyrrolidinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, morpholino,
furanyl, tetrahydrofuranyl, piperidyl, piperazinyl, thiomorpholino,
tetrahydropyranyl, homopiperazinyl, thienyl, imidazolyl,
1,2,4-triazolyl, 1,3,4-triazolyl, indolyl, thiazolyl, thiadiazolyl,
pyrazinyl, pyridazinyl and pyridyl.
[0097] The term "cycloalkyl" refers to a saturated carbocylic ring
containing between 3 to 12 carbon atoms, preferably between 3 and 7
carbon atoms. Examples of C.sub.3-7cycloalkyl include cycloheptyl,
cyclohexyl, cyclopentyl, cyclobutyl or cyclopropyl. Preferably
cyclopropyl, cyclopentyl or cyclohexyl.
[0098] Examples of C.sub.1-6alkyl include methyl, ethyl, propyl,
isopropyl, 1-methyl-propyl, sec-butyl, tert-butyl and
2-ethyl-butyl; examples of C.sub.2-6alkenyl include: ethenyl,
2-propenyl, 2-butenyl, or 2-methyl-2-butenyl; examples of
C.sub.2-6alkynyl include: ethynyl, 2-propynyl, 2-butynyl, or
2-methyl-2-butynyl, examples of --OC.sub.1-6alkyl include methoxy,
ethoxy, propoxy and tert-butoxy; examples of --C(O)OC.sub.1-6alkyl
include methoxycarbonyl, ethoxycarbonyl and tert-butyloxycarbonyl;
examples of --NH--C.sub.1-4alkyl include: ##STR5## and examples of
--N-di-(C.sub.1-4alkyl): ##STR6##
[0099] For the avoidance of doubt, in the definition of linker
group `X`, the right hand side of the group is attached to phenyl
ring and the left hand side is bound to `Y`.
[0100] The invention includes the E and Z isomers of compounds of
the invention defined above, but the preferred compounds are the E
isomers. It is to be understood that, insofar as certain of the
compounds of the invention may exist in optically active or racemic
forms by virtue of one or more asymmetric carbon atoms, the
invention includes in its definition any such optically active or
racemic form which possesses the property of stimulating GLK
directly or inhibiting the GLK/GLKRP interaction. The synthesis of
optically active forms may be carried out by standard techniques of
organic chemistry well known in the art, for example by synthesis
from optically active starting materials or by resolution of a
racemic form.
[0101] Preferred compounds of Formula (I) to (Ic) above or of
Formula (II) to (IIf) below are those wherein any one or more of
the following apply: [0102] (1) m is 0 or 1; [0103] n is 1 or 2;
preferably n is 2; [0104] most preferably m is 0 and n is 2. [0105]
(2) The R.sup.1 and/or R.sup.2 group(s) are attached at the
2-position and/or the 3-position and/or the 5-position; when n+m is
2, the groups are preferably at the 2- and 5- or 3- and
5-positions, most preferably at the 2- and 5-positions. [0106] (3)
each R.sup.1 is independently selected from OH, CH.sub.3-aF.sub.a
(preferably CF.sub.3), OCH.sub.3-aF.sub.a (preferably OCF.sub.3),
halo, C.sub.1-6alkyl (preferably methyl), NO.sub.2 or heterocyclyl
optionally substituted by C1-6alkyl; preferably R.sup.1 is selected
from CH.sub.3-aF.sub.a (preferably CF.sub.3), OCH.sub.3-aF.sub.a
(preferably OCF.sub.3) or halo; [0107] (4) each R.sup.2 is the
group Y--X-- [0108] wherein each X is independently selected from:
[0109] --O-Z-, --C(O)O-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-,
--N(R.sup.6)SO.sub.2, Z-SO.sub.2NH-Z-, --(CH.sub.2).sub.1-4--,
--CH.dbd.CH-Z-, --C.ident.C-Z-, --N(R.sup.6)CO-Z-,
--CON(R.sup.6)-Z- or a direct bond; [0110] Preferably X is
independently selected from: --O-Z-, --S-Z-, --SO-Z-,
--SO.sub.2-Z-, --N(R.sup.6)SO.sub.2,
Z-SO.sub.2NH-Z--(CH.sub.2).sub.1-4-- or a direct bond [0111] Most
preferably X is independently selected from: --O--, --S--, --SO--,
--SO.sub.2--, --(CH.sub.2).sub.1-4-- or a direct bond; [0112] each
Z is independently selected from: [0113] a direct bond or
--(CH.sub.2).sub.1-4-- or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--, wherein
one R.sup.6 group is hydrogen and the other R.sup.6 group is
C.sub.1-4alkyl; [0114] preferably a direct bond,
--(CH.sub.2).sub.0-2-- or ##STR7## [0115] more preferably a direct
bond or --CH.sub.2--. [0116] each Z.sup.1 is independently selected
from: [0117] a direct bond, C.sub.2-6alkenylene or a group of the
formula --(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--,
wherein one R.sup.6 group is hydrogen and the other R.sup.6 group
is C.sub.1-4alkyl; [0118] preferably a direct bond,
--(CH.sub.2).sub.0-2--, C.sub.2-4alkenylene or ##STR8## [0119] more
preferably a direct bond, --(CH.sub.2).sub.0-4--, 2-propenylene or
##STR9## [0120] most preferably --(CH.sub.2).sub.0-3--,
2-propenylene or a direct bond. [0121] and each Y is independently
selected from: [0122] aryl-Z.sup.1-, heterocyclyl-Z.sup.1-,
C.sub.3-7 cycloalkyl-Z.sup.1-, C.sub.1-6 alkyl, C.sub.1-6alkoxy,
C.sub.2-6alkenyl or --CH(OH)CH.sub.3-aF.sub.a; [0123] preferably
each Y is independently selected from: [0124] phenyl-Z.sup.1-,
heterocyclyl-Z.sup.1-, C.sub.3-7 cycloalkyl-Z.sup.1-, C.sub.1-6
alkyl (preferably a branched C.sub.2-6alkyl chain such as isopropyl
or isobutyl), C.sub.2-6alkenyl or --CH.sub.3-aF.sub.a; [0125] most
preferably Y is independently selected from: [0126]
phenyl-Z.sup.1-, morpholinyl-Z.sup.1-, pyridyl-Z.sup.1-,
pyrrolidino-Z.sup.1-, isoxazolyl-Z.sup.1-, diazolyl-Z.sup.1-,
furanyl-Z.sup.1-, thienyl-Z.sup.1-, thiazolyl-Z.sup.1-,
cyclopropy-Z.sup.1- or cyclohexyl-Z.sup.1-, [0127] wherein each Y
is independently optionally substituted by R.sup.4. [0128] (5) each
R.sup.2 is the group Y--X--, Z within the definition of X is a
direct bond and Z.sup.1 within the definition of Y is a group of
the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--. [0129]
most preferably R.sup.2 is independently selected from: methoxy,
methylthio, methylsulphinyl, methylsulphonyl, ethoxy, iso-propoxy,
pentyloxy, phenoxy, benzyloxy, phenylpropoxy, phenylallyloxy,
phenylthio, diazolylmethoxy, diazolylethoxy, furanylmethoxy,
isoxazolylmethoxy, morpholino, pyridylmethoxy, pyrrolidinylethoxy,
thiazolyl, thiazolylmethoxy, thiazolylethoxy, thienylmethoxy,
cyclopropylmethoxy or cyclohexylmethoxy, wherein each of these
R.sup.2 groups is optionally substituted by R.sup.4. [0130] (6)
each R.sup.4 is independently selected from: [0131] halo,
--CH.sub.3-aF.sub.a, --OCH.sub.3-aF.sub.a, CN, NO.sub.2,
C.sub.1-6alkyl, C.sub.1-6alkoxy, --COOH, --(CH.sub.2).sub.1-3COOH,
--(CH.sub.2).sub.0-3COOH, --C(O)phenyl, --C(O)NH.sub.2,
--C(O)NH-phenyl, --SO.sub.2NH.sub.2, --SO.sub.2C.sub.1-6alkyl,
phenyl optionally substituted by C.sub.1-6alkyl or
--C(O)OC.sub.1-6alkyl; [0132] More preferably R.sup.4 is
independently selected from. chloro, bromo, fluoro, methyl,
tert-butyl, isopropyl, methoxy, C.sub.1-4alkoxycarbonyl, vinyl, CN,
OH, trifluoromethyl, --COOH, --CH.sub.2COOH, NO.sub.2,
methylsulphonyl, --C(O)NH.sub.2, --C(O)NH-phenyl,
--SO.sub.2NH.sub.2 or benzyloxy, [0133] (7) R.sup.3 is selected
from hydrogen or C.sub.1-6alkyl; preferably R.sup.3 is selected
from hydrogen or methyl; most preferably R.sup.3 is hydrogen.
[0134] According to a further feature of the invention there is
provided the following preferred groups of compounds of the
invention: (I) a Compound of Formula (II) ##STR10## [0135] wherein:
[0136] A, X, Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a
compound of Formula (I); or a salt, solvate or pro-drug thereof.
(II) a Compound of Formula (IIa) ##STR11## [0137] wherein: [0138]
Het is a monocyclic heterocyclyl, optionally substituted with
between 1 and 3 groups selected from R.sup.4 and, [0139] A, X,
Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a compound of
Formula (I); or a salt, solvate or pro-drug thereof. (III) a
Compound of Formula (IIb) ##STR12## [0140] wherein: [0141] the
C.sub.1-6alkyl group is optionally substituted with between 1 and 3
groups selected from R.sup.4, preferably unsubstituted; [0142] the
C.sub.1-6alkyl group optionally contains a double bond, preferably
the C.sub.1-6alkyl group does not contains a double bond; and
[0143] A, X, Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a
compound of Formula (I); [0144] with the proviso that: [0145] when
A is pyridyl, R.sup.3 is OH, phenyl-Z.sup.1-X-- is
phenyl-CH.sub.2--O-- wherein the phenyl ring is unsubstituted, then
C.sub.1-6alkyl-X-- must be other than CH.sub.3--S-- or
CH.sub.3--SO.sub.2--; [0146] or a salt, solvate or pro-drug
thereof. (IV) a Compound of Formula (IIc) ##STR13## [0147] wherein:
[0148] the C.sub.3-7cycloalkyl group is optionally substituted with
between 1 and 3 groups selected from R.sup.4, and [0149] A, X,
Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a compound of
Formula (I); or a salt, solvate or pro-drug thereof. (V) a Compound
of Formula (IId) ##STR14## [0150] wherein: [0151] the
C.sub.1-6alkyl groups are independently optionally substituted with
between 1 and 3 groups selected from R.sup.4, preferably one of the
C.sub.1-6alkyl groups is unsubstituted, [0152] the C.sub.1-6alkyl
groups independently optionally contain a double bond, preferably
only one of the C.sub.1-6alkyl groups contain a double bond,
preferably neither of the C.sub.1-6alkyl group contains a double
bond, and [0153] A, X, R.sup.3 and R.sup.4 are as defined above in
a compound of Formula (I); [0154] with the proviso that A is other
than pyridyl, furanyl or thiazolyl; [0155] or a salt, solvate or
pro-drug thereof. (VI) a Compound of Formula (IIe) ##STR15## [0156]
wherein: [0157] the C.sub.3-7cycloalkyl and C.sub.1-6alkyl groups
are independently optionally substituted with between 1 and 3
groups selected from R.sup.4, preferably the C.sub.1-6alkyl group
is unsubstituted; the C.sub.1-6alkyl group optionally contains a
double bond, preferably the C.sub.1-6alkyl group does not contains
a double bond; and [0158] A, X, Z.sup.1, R.sup.3 and R.sup.4 are as
defined above in a compound of Formula (I); [0159] or a salt,
solvate or pro-drug thereof. (VII) a Compound of Formula (IIf)
##STR16## [0160] wherein: [0161] Het is a monocyclic heterocyclyl,
[0162] the Het and C.sub.1-6alkyl groups are independently
optionally substituted with between 1 and 3 groups selected from
R.sup.4, preferably the C.sub.1-6alkyl group is unsubstituted;
[0163] the C.sub.1-6alkyl group optionally contains a double bond,
preferably the C.sub.1-6alkyl group does not contains a double
bond; and [0164] A, X, Z.sup.1, R.sup.3 and R.sup.4 are as defined
above in a compound of Formula (I); [0165] or a salt, solvate or
pro-drug thereof. (VIII) a Compound of Formula (IIg) ##STR17##
[0166] wherein: [0167] Het is a monocyclic heterocyclyl, [0168] the
Het and C.sub.3-7cycloalkyl groups are independently optionally
substituted with between 1 and 3 groups selected from R.sup.4, and
[0169] A, X, Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a
compound of Formula (I); [0170] or a salt, solvate or pro-drug
thereof. (IX) a Compound of Formula (IIh) ##STR18## [0171] wherein:
[0172] Y is aryl-Z.sup.1-, wherein aryl is preferably a partially
saturated bicyclic carbocyclic ring; [0173] Y and the
C.sub.1-6alkyl group are independently optionally substituted with
between 1 and 3 groups selected from R.sup.4, preferably the
C.sub.1-6alkyl group is unsubstituted, [0174] the C.sub.1-6alkyl
group optionally contains a double bond, preferably the
C.sub.1-6alkyl group does not contains a double bond; and [0175] A,
X, Z.sup.1, R.sup.3 and R.sup.4 are as defined above in a compound
of Formula (I); [0176] or a salt, solvate or pro-drug thereof. (X)
a Compound of Formula (IIj) ##STR19## [0177] wherein: [0178] X is
selected from --SO.sub.2N(R.sup.6)-Z- or --N(R.sup.6)SO.sub.2-Z-,
preferably X is --SO.sub.2N(R.sup.6)-Z-; [0179] Z is as described
above, preferably Z is propylene, ethylene or methylene, more
preferably Z is methylene; [0180] Z.sup.a is selected from a direct
bond or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--;
preferably Z.sup.a is selected from C.sub.1-2alkylene or a direct
bond; preferably Z.sup.a is a direct bond; [0181] R.sup.6 is
selected from: C.sub.1-4alkyl or hydrogen, preferably methyl or
hydrogen; [0182] Y is selected from aryl-Z.sup.1- or
heterocyclyl-Z.sup.1-; [0183] Y and the C.sub.1-6alkyl group are
independently optionally substituted with between 1 and 3 groups
selected from R.sup.4, [0184] the C.sub.1-6alkyl group optionally
contains a double bond, preferably the C.sub.1-6alkyl group does
not contain a double bond, and [0185] A, Z.sup.1, R.sup.3 and
R.sup.4 are as defined above in a compound of Formula (I); [0186]
or a salt, solvate or pro-drug thereof.
[0187] A further preferred groups of compounds of the invention in
either of groups (I)-(IX) above is wherein: [0188] X is
independently selected from: --O-Z-, SO.sub.2N(R.sup.6)-Z- or
--N(R.sup.6)-Z-; [0189] Z is a direct bond or --CH.sub.2--; [0190]
Z.sup.1 is selected from a direct bond,
--CH.sub.2--(CH.sub.2).sub.2-- or ##STR20## and [0191] R.sup.3 is
as defined above in a compound of Formula (I); [0192] or a salt,
solvate or pro-drug thereof.
[0193] In a further embodiment of the invention there is provided a
compound as defined in either of groups (I) to (X) above
wherein:
[0194] A is selected from: pyridyl, pyrimidinyl, pyrazinyl, furanyl
or thiazolyl; preferably A is linked to the styryl group at the
2-position of A.
[0195] In a further embodiment of the invention there is provided a
compound as defined in either of groups (I) to (X) above wherein
the two Y--X-- groups are linked to the phenyl ring in a 2, 5
orientation relative to the styryl group.
[0196] The compounds of the invention may be administered in the
form of a pro-drug. A pro-drug is a bioprecursor or
pharmaceutically acceptable compound being degradable in the body
to produce a compound of the invention (such as an ester or amide
of a compound of the invention, particularly an in vivo
hydrolysable ester). Various forms of prodrugs are known in the
art. For examples of such prodrug derivatives, see: [0197] a)
Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and
Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et
al. (Academic Press, 1985); [0198] b) A Textbook of Drug Design and
Development, edited by Krogsgaard-Larsen; [0199] c) H. Bundgaard,
Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p.
113-191 (1991); [0200] d) H. Bundgaard, Advanced Drug Delivery
Reviews, 8, 1-38 (1992); [0201] e) H. Bundgaard, et al., Journal of
Pharmaceutical Sciences, 77, 285 (1988); and [0202] f) N. Kakeya,
et al., Chem Pharm Bull, 32, 692 (1984). The contents of the above
cited documents are incorporated herein by reference.
[0203] Examples of pro-drugs are as follows. An in-vivo
hydrolysable ester of a compound of the invention containing a
carboxy or a hydroxy group is, for example, a
pharmaceutically-acceptable ester which is hydrolysed in the human
or animal body to produce the parent acid or alcohol. Suitable
pharmaceutically-acceptable esters for carboxy include C.sub.1 to
C.sub.6alkoxymethyl esters for example methoxymethyl, C.sub.1 to
.sub.6alkanoyloxymethyl esters for example pivaloyloxymethyl,
phthalidyl esters, C.sub.3 to .sub.8cycloalkoxycarbonyloxyC.sub.1
to .sub.6alkyl esters for example 1-cyclohexylcarbonyloxyethyl;
1,3-dioxolen-2-onylmethyl esters, for example
5-methyl-1,3-dioxolen-2-onylmethyl; and
C.sub.1-6alkoxycarbonyloxyethyl esters.
[0204] An in-vivo hydrolysable ester of a compound of the invention
containing a hydroxy group includes inorganic esters such as
phosphate esters (including phosphoramidic cyclic esters) and
.alpha.-acyloxyalkyl ethers and related compounds which as a result
of the in-vivo hydrolysis of the ester breakdown to give the parent
hydroxy group/s. Examples of .alpha.-acyloxyalkyl ethers include
acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of
in-vivo hydrolysable ester forming groups for hydroxy include
alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and
phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters),
dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to
give carbamates), dialkylaminoacetyl and carboxyacetyl.
[0205] A suitable pharmaceutically-acceptable salt of a compound of
the invention is, for example, an acid-addition salt of a compound
of the invention which is sufficiently basic, for example, an
acid-addition salt with, for example, an inorganic or organic acid,
for example hydrochloric, hydrobromic, sulphuric, phosphoric,
trifluoroacetic, citric or maleic acid. In addition a suitable
pharmaceutically-acceptable salt of a benzoxazinone derivative of
the invention which is sufficiently acidic is an alkali metal salt,
for example a sodium or potassium salt, an alkaline earth metal
salt, for example a calcium or magnesium salt, an ammonium salt or
a salt with an organic base which affords a
physiologically-acceptable cation, for example a salt with
methylamine, dimethylamine, trimethylamine, piperidine, morpholine
or tris-(2-hydroxyethyl)amine.
[0206] A further feature of the invention is a pharmaceutical
composition comprising a compound of Formula (I) to (Ic) or (II) to
(IIj) as defined above, or a salt, solvate or prodrug thereof,
together with a pharmaceutically-acceptable diluent or carrier.
[0207] According to another aspect of the invention there is
provided a compound of Formula (Ib) or (Ic), or (II) to (IIj) as
defined above for use as a medicament; with the proviso that [0208]
(i) when A is pyridyl or thiazolyl, m is 1 or 2 and n is 0, R.sup.3
is OH or --O--C.sub.1-6alkyl, then R.sup.1 is other than halo,
amino or nitro; [0209] (ii) when A is pyridyl, m=0, n=1, X is
--N(CH.sub.3)-- or --N(CH.sub.3)--CH.sub.2--, R.sup.3 is OH, then Y
cannot be methyl; [0210] (iii) when A is thiazolyl, m is 0, R.sup.3
is OH, then when n is 2 (R.sup.2).sub.n cannot be
di-C.sub.1-alkyl-O-- or C.sub.1-6alkyl-O--C.sub.1-6alkenyl-O-- and
when n is 3 (R.sup.2).sub.n cannot be tri-C.sub.1-6alkyl-O--;
[0211] (iv) when A is pyridyl, m is 0 or m is 1 and R.sup.1 is
halo, n is 1 and R.sup.2 is phenyl-CH.sub.2--O--, then R.sup.3
cannot be OH; and [0212] (v) when A is pyridyl, R.sup.3 is OH, m is
0, n is 2 and one of the R.sup.2 groups is phenyl-CH.sub.2--O--,
then the other R.sup.2 group must be other than CH.sub.3--S-- or
CH.sub.3--SO.sub.2--.
[0213] Further according to the invention there is provided a
compound of Formula (Ib) or (Ic), or (II) to (IIj) for use in the
preparation of a medicament for treatment of a disease mediated
through GLK, in particular type 2 diabetes.
The compound is suitably formulated as a pharmaceutical composition
for use in this way.
[0214] According to another aspect of the present invention there
is provided a method of treating GLK mediated diseases, especially
diabetes, by administering an effective amount of a compound of
Formula (Ib) or (Ic), or (II) to (IIj) to a mammal in need of such
treatment.
[0215] Specific disease which may be treated by the compound or
composition of the invention include: blood glucose lowering in
Diabetes Mellitus type 2 without a serious risk of hypoglycaemia
(and potential to treat type 1), dyslipidemea, obesity, insulin
resistance, metabolic syndrome X, impaired glucose tolerance.
[0216] Specific disease which may be treated by the compound or
composition of the invention include: blood glucose lowering in
Diabetes Mellitus type 2 (and potential to treat type 1);
dyslipidaemia; obesity; insulin resistance; metabolic syndrome X;
impaired glucose tolerance; polycystic ovary syndrome.
[0217] The compositions of the invention may be in a form suitable
for oral use (for example as tablets, lozenges, hard or soft
capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for
example as creams, ointments, gels, or aqueous or oily solutions or
suspensions), for administration by inhalation (for example as a
finely divided powder or a liquid aerosol), for administration by
insufflation (for example as a finely divided powder) or for
parenteral administration (for example as a sterile aqueous or oily
solution for intravenous, subcutaneous, intramuscular or
intramuscular dosing or as a suppository for rectal dosing).
[0218] The compositions of the invention may be obtained by
conventional procedures using conventional pharmaceutical
excipients, well known in the art. Thus, compositions intended for
oral use may contain, for example, one or more colouring,
sweetening, flavouring and/or preservative agents.
[0219] Suitable pharmaceutically acceptable excipients for a tablet
formulation include, for example, inert diluents such as lactose,
sodium carbonate, calcium phosphate or calcium carbonate,
granulating and disintegrating agents such as corn starch or
algenic acid; binding agents such as starch; lubricating agents
such as magnesium stearate, stearic acid or talc; preservative
agents such as ethyl or propyl p-hydroxybenzoate, and
anti-oxidants, such as ascorbic acid. Tablet formulations may be
uncoated or coated either to modify their disintegration and the
subsequent absorption of the active ingredient within the
gastrointestinal tract, or to improve their stability and/or
appearance, in either case, using conventional coating agents and
procedures well known in the art.
[0220] Compositions for oral use may be in the form of hard gelatin
capsules in which the active ingredient is mixed with an inert
solid diluent, for example, calcium carbonate, calcium phosphate or
kaolin, or as soft gelatin capsules in which the active ingredient
is mixed with water or an oil such as peanut oil, liquid paraffin,
or olive oil.
[0221] Aqueous suspensions generally contain the active ingredient
in finely powdered form together with one or more suspending
agents, such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents such as lecithin or condensation products of an
alkylene oxide with fatty acids (for example polyoxethylene
stearate), or condensation products of ethylene oxide with long
chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,
or condensation products of ethylene oxide with partial esters
derived from fatty acids and a hexitol such as polyoxyethylene
sorbitol monooleate, or condensation products of ethylene oxide
with long chain aliphatic alcohols, for example
heptadecaethyleneoxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and a hexitol
such as polyoxyethylene sorbitol monooleate, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more
preservatives (such as ethyl or propyl p-hydroxybenzoate,
anti-oxidants (such as ascorbic acid), colouring agents, flavouring
agents, and/or sweetening agents (such as sucrose, saccharine or
aspartame).
[0222] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil (such as arachis oil, olive oil,
sesame oil or coconut oil) or in a mineral oil (such as liquid
paraffin). The oily suspensions may also contain a thickening agent
such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set out above, and flavouring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0223] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water generally contain
the active ingredient together with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients such as sweetening,
flavouring and colouring agents, may also be present.
[0224] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, such as olive oil or arachis oil, or a mineral oil,
such as for example liquid paraffin or a mixture of any of these.
Suitable emulsifying agents may be, for example,
naturally-occurring gums such as gum acacia or gum tragacanth,
naturally-occurring phosphatides such as soya bean, lecithin, an
esters or partial esters derived from fatty acids and hexitol
anhydrides (for example sorbitan monooleate) and condensation
products of the said partial esters with ethylene oxide such as
polyoxyethylene sorbitan monooleate. The emulsions may also contain
sweetening, flavouring and preservative agents.
[0225] Syrups and elixirs may be formulated with sweetening agents
such as glycerol, propylene glycol, sorbitol, aspartame or sucrose,
and may also contain a demulcent, preservative, flavouring and/or
colouring agent.
[0226] The pharmaceutical compositions may also be in the form of a
sterile injectable aqueous or oily suspension, which may be
formulated according to known procedures using one or more of the
appropriate dispersing or wetting agents and suspending agents,
which have been mentioned above. A sterile injectable preparation
may also be a sterile injectable solution or suspension in a
non-toxic parenterally-acceptable diluent or solvent, for example a
solution in 1,3-butanediol.
[0227] Compositions for administration by inhalation may be in the
form of a conventional pressurised aerosol arranged to dispense the
active ingredient either as an aerosol containing finely divided
solid or liquid droplets. Conventional aerosol propellants such as
volatile fluorinated hydrocarbons or hydrocarbons may be used and
the aerosol device is conveniently arranged to dispense a metered
quantity of active ingredient.
[0228] For further information on formulation the reader is
referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal
Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon
Press 1990.
[0229] The amount of active ingredient that is combined with one or
more excipients to produce a single dosage form will necessarily
vary depending upon the host treated and the particular route of
administration. For example, a formulation intended for oral
administration to humans will generally contain, for example, from
0.5 mg to 2 g of active agent compounded with an appropriate and
convenient amount of excipients which may vary from about 5 to
about 98 percent by weight of the total composition. Dosage unit
forms will generally contain about 1 mg to about 500 mg of an
active ingredient. For further information on Routes of
Administration and Dosage Regimes the reader is referred to Chapter
25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin
Hansch; Chairman of Editorial Board), Pergamon Press 1990.
[0230] The size of the dose for therapeutic or prophylactic
purposes of a compound of the Formula (I), (Ia), (Ib) or (Ic) will
naturally vary according to the nature and severity of the
conditions, the age and sex of the animal or patient and the route
of administration, according to well known principles of
medicine.
[0231] In using a compound of the Formula (I), (Ia), (Ib) or (Ic)
for therapeutic or prophylactic purposes it will generally be
administered so that a daily dose in the range, for example, 0.5 mg
to 75 mg per kg body weight is received, given if required in
divided doses. In general lower doses will be administered when a
parenteral route is employed. Thus, for example, for intravenous
administration, a dose in the range, for example, 0.5 mg to 30 mg
per kg body weight will generally be used. Similarly, for
administration by inhalation, a dose in the range, for example, 0.5
mg to 25 mg per kg body weight will be used. Oral administration is
however preferred.
[0232] The elevation of GLK activity described herein may be
applied as a sole therapy or may involve, in addition to the
subject of the present invention, one or more other substances
and/or treatments. Such conjoint treatment may be achieved by way
of the simultaneous, sequential or separate administration of the
individual components of the treatment. Simultaneous treatment may
be in a single tablet or in separate tablets. For example in the
treatment of diabetes mellitus chemotherapy may include the
following main categories of treatment: [0233] 1) Insulin and
insulin analogues; [0234] 2) Insulin secretagogues including
sulphonylureas (for example glibenclamide, glipizide) and prandial
glucose regulators (for example repaglinide, nateglinide); [0235]
3) Insulin sensitising agents including PPARg agonists (for example
pioglitazone and rosiglitazone); [0236] 4) Agents that suppress
hepatic glucose output (for example metformin). [0237] 5) Agents
designed to reduce the absorption of glucose from the intestine
(for example acarbose); [0238] 6) Agents designed to treat the
complications of prolonged hyperglycaemia; [0239] 7) Anti-obesity
agents (for example sibutramine and orlistat); [0240] 8)
Anti-dyslipidaemia agents such as, HMG-CoA reductase inhibitors
(statins, eg pravastatin); PPAR.alpha. agonists (fibrates, eg
gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol
absorption inhibitors (plant stanols, synthetic inhibitors); bile
acid absorption inhibitors (IBATi) and nicotinic acid and analogues
(niacin and slow release formulations); [0241] 9) Antihypertensive
agents such as, .beta. blockers (eg atenolol, inderal); ACE
inhibitors (eg lisinopril); Calcium antagonists (eg. nifedipine);
Angiotensin receptor antagonists (eg candesartan), .alpha.
antagonists and diuretic agents (eg. furosemide, benzthiazide);
[0242] 10) Haemostasis modulators such as, antithrombotics,
activators of fibrinolysis and antiplatelet agents; thrombin
antagonists; factor Xa inhibitors; factor VIIa inhibitors);
antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants
(heparin and Low molecular weight analogues, hirudin) and warfarin;
and [0243] 11) Anti-inflammatory agents, such as non-steroidal
anti-inflammatory drugs (eg. aspirin) and steroidal
anti-inflammatory agents (eg. cortisone).
[0244] According to another aspect of the present invention there
is provided individual compounds produced as end products in the
Examples set out below and salts thereof.
[0245] A compound of the invention, or a salt, pro-drug or solvate
thereof, may be prepared by any process known to be applicable to
the preparation of such compounds or structurally related
compounds. Such processes are illustrated by the following
representative schemes (1 to 4) in which variable groups have any
of the meanings defined for Formula (I) unless stated otherwise and
A is for example depicted as pyridyl. Functional groups may be
protected and deprotected using conventional methods.
[0246] For examples of protecting groups such as amino and
carboxylic acid protecting groups (as well as means of formation
and eventual deprotection), see T. W. Greene and P. G. M. Wuts,
"Protective Groups in Organic Synthesis", Second Edition, John
Wiley & Sons, New York, 1991. Note abbreviations used have been
listed immediately before the Examples below. ##STR21## ##STR22##
##STR23## ##STR24## During the preparation process, it may be
advantageous to use a protecting group for a functional group
within the molecule. Protecting groups may be removed by any
convenient method as described in the literature or known to the
skilled chemist as appropriate for the removal of the protecting
group in question, such methods being chosen so as to effect
removal of the protecting group with minimum disturbance of groups
elsewhere in the molecule.
[0247] Processes for the synthesis of compounds of Formula (I) are
provided as a further feature of the invention. Thus, according to
a further aspect of the invention there is provided a process for
the preparation of a compound of Formula (I) which comprises:
[0248] (a) reaction of a compound of Formula (IIIa) with a compound
of Formula (IIIb), ##STR25## [0249] (b) for compounds of Formula
(I) wherein R.sup.3 is hydrogen, de-protection of a compound of
Formula (IIIc), ##STR26## [0250] wherein P.sup.1 is a protecting
group; [0251] (c) reaction of a compound of Formula (IIId) with a
compound of Formula (IIIe), ##STR27## [0252] wherein X' and X''
comprises groups which when reacted together form the group X;
[0253] (d) for a compound of Formula (I) wherein X or X.sup.1 is
--SO-Z- or --SO.sub.2-Z-, oxidation of the corresponding compound
of Formula (I) wherein X or X.sup.1 respectively is --S-Z-; or
[0254] (e) for a compound of Formula (I) wherein R.sup.3 is
NHR.sup.6, reaction of a compound of Formula (IIIf) with a compound
of Formula (IIIg), ##STR28## and thereafter, if necessary: i)
converting a compound of Formula (I) into another compound of
Formula (I); ii) removing any protecting groups; iii) forming a
salt, pro-drug or solvate thereof.
[0255] Specific reaction conditions for the above reactions are as
follows:
Process a)--as described above in Scheme 1;
Process b)--as described above in Scheme 1/2
Process c)--examples of this process are as follows:
[0256] (i) to form a group when X is --O-Z-, X' is a group of
formula HO-Z- and X'' is a leaving group (alternatively X' is a
group of formula L.sup.2-Z- wherein L.sup.2 is a leaving group and
X'' is a hydroxyl group), compounds of Formula (IIId) and (IIIe)
are reacted together in a suitable solvent, such as DMF or THF,
with a base such as sodium hydride or potassium tert-butoxide, at a
temperature in the range 0 to 100.degree. C., optionally using
metal catalysis such as palladium on carbon or cuprous iodide;
[0257] (ii) to form a group when X is N(R.sup.6)-Z-, X' is a group
of formula H--(R.sup.6)N-Z- and X'' is a leaving group
(alternatively X' is a group of formula L.sup.2-Z- wherein L.sup.2
is a leaving group and X'' is a group or formula --N(R.sup.6)--H),
compounds of Formula (IIId) and (IIIe) are reacted together in a
suitable solvent such as THF, an alcohol or acetonitrile, using a
reducing agent such as sodium cyano borohydride or sodium
trisacetoxyborohydride at room temperature; [0258] (iii) to form a
group when X is --SO.sub.2N(R.sup.6)-Z-, X'' is a group of formula
H--N(R.sup.6)-Z- wherein L.sup.2 is a leaving group and X'' is an
activated sulphonyl group such as a group of formula
--SO.sub.2--Cl, compounds of Formula (IIId) and (IIIe) are reacted
together in a suitable solvent such as methylene chloride, THF or
pyridine, in the presence of a base such as triethylamine or
pyridine at room temperature; [0259] (iv) to form a group when X is
--N(R.sup.6)SO.sub.2-Z-, X' is an activated sulphonyl group such as
a group of formula Cl--SO.sub.2-Z- group and X'' is a group of
formula --N(R.sup.6)-L.sup.2 wherein L.sup.2 is a leaving group,
compounds of Formula (IIId) and (IIIe) are reacted together in a
suitable solvent such as methylene chloride, THF or pyridine, in
the presence of a base such as triethylamine or pyridine at room
temperature; [0260] (v) to form a group when X is
--C(O)N(R.sup.6)-Z-, X' is a group of formula H--N(R.sup.6)-Z-
wherein L.sup.2 is a leaving group and X'' is an activated carbonyl
group such as a group of formula --C(O)--Cl, compounds of Formula
(IIId) and (IIIe) are reacted together in a suitable solvent such
as THF or methylene chloride, in the presence of a base such as
triethylamine or pyridine at room temperature; [0261] (vi) to form
a group when X is --N(R.sup.6)C(O)-Z-, X' is an activated carbonyl
group such as a group of formula Cl--C(O)-Z- group and X'' is a
group of formula --N(R.sup.6)-L.sup.2 wherein L.sup.2 is a leaving
group, compounds of Formula (IIId) and (IIIe) are reacted together
in a suitable solvent such as THF or methylene chloride, in the
presence of a base such as triethylamine or pyridine at room
temperature; [0262] (vii) to form a group when X is --CH.dbd.CH-Z-,
a Wittag reaction or a Wadsworth-Emmans Horner reaction can be
used. For example, X' terminates in an aldehyde group and Y--X'' is
a phosphine derivative of the formula Y--C.sup.-H--P.sup.+PH.sub.3
which can be reacted together in a strong base such as sodium
hydride or potassium tert-butoxide, in a suitable solvent such as
THF at a temperature between room temperature and 100.degree. C.
Process d)--the oxidization of a compound of Formula (I) wherein X
or X.sup.1 is --S-Z- is well known in the art, for example,
reaction with metachloroperbenzoic acid (MCPBA) is the presence of
a suitable solvent such as dichloromethane at ambient temperature.
If an excess of MCPBA is used a compound of Formula (I) wherein X
is --S(O.sub.2)-- is obtained. Process e)--as described above in
Scheme 4.
[0263] Protecting groups may be removed by any convenient method as
described in the literature or known to the skilled chemist as
appropriate for the removal of the protecting group in question,
such methods being chosen so as to effect removal of the protecting
group with minimum disturbance of groups elsewhere in the
molecule.
[0264] Specific examples of protecting groups are given below for
the sake of convenience, in which "lower" signifies that the group
to which it is applied preferably has 1-4 carbon atoms. It will be
understood that these examples are not exhaustive. Where specific
examples of methods for the removal of protecting groups are given
below these are similarly not exhaustive. The use of protecting
groups and methods of deprotection not specifically mentioned is of
course within the scope of the invention.
[0265] A carboxy protecting group may be the residue of an
ester-forming aliphatic or araliphatic alcohol or of an
ester-forming silanol (the said alcohol or silanol preferably
containing 1-20 carbon atoms). Examples of carboxy protecting
groups include straight or branched chain (C.sub.1-12)alkyl groups
(e.g. isopropyl, t-butyl); lower alkoxy lower alkyl groups (e.g.
methoxymethyl, ethoxymethyl, isobutoxymethyl; lower aliphatic
acyloxy lower alkyl groups, (e.g. acetoxymethyl,
propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower
alkoxycarbonyloxy lower alkyl groups (e.g.
1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower
alkyl groups (e.g. p-methoxybenzyl, Q-nitrobenzyl, p-nitrobenzyl,
benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (e.g.
trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl
lower alkyl groups (e.g. trimethylsilylethyl); and (2-6C)alkenyl
groups (e.g. allyl and vinylethyl).
[0266] Methods particularly appropriate for the removal of carboxyl
protecting groups include for example acid-, metal- or
enzymically-catalysed hydrolysis.
[0267] Examples of hydroxy protecting groups include lower alkenyl
groups (e.g. allyl); lower alkanoyl groups (e.g. acetyl); lower
alkoxycarbonyl groups (e.g. t-butoxycarbonyl); lower
alkenyloxycarbonyl groups (e.g. allyloxycarbonyl); aryl lower
alkoxycarbonyl groups (e.g. benzoyloxycarbonyl,
p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl,
p-nitrobenzyloxycarbonyl); tri lower alkyl/arylsilyl groups (e.g.
trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl); aryl
lower alkyl groups (e.g. benzyl) groups; and triaryl lower alkyl
groups (e.g. triphenylmethyl).
[0268] Examples of amino protecting groups include formyl, aralkyl
groups (e.g. benzyl and substituted benzyl, e.g. p-methoxybenzyl,
nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl);
di-p-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl
(e.g. t-butoxycarbonyl); lower alkenyloxycarbonyl (e.g.
allyloxycarbonyl); aryl lower alkoxycarbonyl groups (e.g.
benzyloxycarbonyl, p-methoxybenzyloxycarbonyl,
o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl; trialkylsilyl
(e.g. trimethylsilyl and t-butyldimethylsilyl); alkylidene (e.g.
methylidene); benzylidene and substituted benzylidene groups.
[0269] Methods appropriate for removal of hydroxy and amino
protecting groups include, for example, acid-, base, metal- or
enzymically-catalysed hydrolysis, or photolytically for groups such
as o-nitrobenzyloxycarbonyl, or with fluoride ions for silyl
groups.
[0270] Examples of protecting groups for amide groups include
aralkoxymethyl (e.g. benzyloxymethyl and substituted
benzyloxymethyl); alkoxymethyl (e.g. methoxymethyl and
trimethylsilylethoxymethyl); tri alkyl/arylsilyl (e.g.
trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl); tri
alkyl/arylsilyloxymethyl (e.g. t-butyldimethylsilyloxymethyl,
t-butyldiphenylsilyloxymethyl); 4-alkoxyphenyl (e.g.
4-methoxyphenyl); 2,4-di(alkoxy)phenyl (e.g. 2,4-dimethoxyphenyl);
4-alkoxybenzyl (e.g. 4-methoxybenzyl); 2,4-di(alkoxy)benzyl (e.g.
2,4-di(methoxy)benzyl); and alk-1-enyl (e.g. allyl, but-1-enyl and
substituted vinyl e.g. 2-phenylvinyl).
[0271] Aralkoxymethyl, groups may be introduced onto the amide
group by reacting the latter group with the appropriate
aralkoxymethyl chloride, and removed by catalytic hydrogenation.
Alkoxymethyl, tri alkyl/arylsilyl and tri alkyl/silyloxymethyl
groups may be introduced by reacting the amide with the appropriate
chloride and removing with acid; or in the case of the silyl
containing groups, fluoride ions. The alkoxyphenyl and alkoxybenzyl
groups are conveniently introduced by arylation or alkylation with
an appropriate halide and removed by oxidation with ceric ammonium
nitrate. Finally alk-1-enyl groups may be introduced by reacting
the amide with the appropriate aldehyde and removed with acid.
[0272] The present invention also relates to the use of a GLK
activator for the combined treatment of diabetes and obesity. GLK
and GLKRP and the K.sub.ATP channel are expressed in neurones of
the hypothalamus, a region of the brain that is important in the
regulation of energy balance and the control of food intake
[14-18]. These neurones have been shown to express orectic and
anorectic neuropeptides [15, 19, 20) and have been assumed to be
the glucose-sensing neurones within the hypothalamus that are
either inhibited or excited by changes in ambient glucose
concentrations [17, 19, 21, 22]. The ability of these neurones to
sense changes in glucose levels is defective in a variety of
genetic and experimentally induced models of obesity [23-28].
Intracerebroventricular (icv) infusion of glucose analogues, that
are competitive inhibitors of glucokinase, stimulate food intake in
lean rats [29, 30]. In contrast, icv infusion of glucose suppresses
feeding [31]. Thus, small molecule activators of GLK may decrease
food intake and weight gain through central effects on GLK.
Therefore, GLK activators may be of therapeutic use in treating
eating disorders, including obesity, in addition to diabetes. The
hypothalamic effects will be additive or synergistic to the effects
of the same compounds acting in the liver and/or pancreas in
normalising glucose homeostasis, for the treatment of Type 2
diabetes. Thus the GLK/GLKRP system can be described as a potential
"Diabesity" target (of benefit in both Diabetes and Obesity).
[0273] This according to a second aspect of the invention there is
provided the use of a GLK activator in the preparation of a
medicament for the combined treatment or prevention of diabetes and
obesity.
[0274] According to a further feature of the second aspect of the
invention there is provided a method of combined treatment, in a
warm-blooded animal, of diabetes and obesity, comprising
administering a therapeutically effective amount of a compound of a
GLK activator, or a pharmaceutically-acceptable salt, pro-drug or
solvate thereof.
[0275] According to a further feature of the second aspect of the
invention there is provided a pharmaceutical composition comprising
a GLK activator, or a pharmaceutically acceptable salt, prodrug or
solvate thereof, in admixture with a pharmaceutically-acceptable
diluent or carrier for the combined treatment of diabetes and
obesity in a warm-blooded animal.
[0276] According to a further feature of the second aspect of the
invention there is provided the use a GLK activator in the
preparation of a medicament for the treatment or prevention of
diabetes and obesity, wherein the GLK activator is a compound of
Formula (I) above.
[0277] According to a further feature of the second aspect of the
invention there is provided a method of combined treatment, in a
warm-blooded animal, of diabetes and obesity, comprising
administering a therapeutically effective amount of a compound of a
GLK activator, or a pharmaceutically-acceptable salt, pro-drug or
solvate thereof, wherein the GLK activator is a compound of Formula
(I) above.
[0278] According to a further feature of the second aspect of the
invention there is provided a pharmaceutical composition comprising
a GLK activator, or a pharmaceutically acceptable salt, prodrug or
solvate thereof, in admixture with a pharmaceutically-acceptable
diluent or carrier for the combined treatment of diabetes and
obesity in a warm-blooded animal, wherein the GLK activator is a
compound of Formula (I) above.
[0279] According to a further feature of the second aspect of the
invention there is provided the use a GLK activator in the
preparation of a medicament for the treatment or prevention of
diabetes and obesity, wherein the GLK activator is a compound of
Formula (IV) below. ##STR29## wherein [0280] m is 0, 1 or 2; [0281]
n is 0, 1, 2, 3 or 4; [0282] and n+m>0; [0283] each R.sup.1 is
independently selected from OH, --(CH.sub.2).sub.1-4OH,
--CH.sub.3-aF.sub.a, --(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a, halo,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2,
NH.sub.2, --NH--C.sub.1-4alkyl, --N-di-(C.sub.1-4alkyl), CN or
formyl; [0284] each R.sup.2 is the group Y--X-- [0285] wherein each
X is a linker independently selected from: [0286] --O-Z-,
--O-Z-O-Z-, --C(O)O-Z-, --OC(O)-Z-, --S-Z-, --SO-Z-, --SO.sub.2-Z-,
--N(R.sup.6)-Z-, --N(R.sup.6)SO.sub.2-Z-, --SO.sub.2N(R.sup.6)-Z-,
--(CH.sub.2).sub.1-4--, --CH.dbd.CH-Z-, --C.dbd.C-Z-,
--N(R.sup.6)CO-Z-, --CON(R.sup.6)-Z-,
--C(O)N(R.sup.6)S(O).sub.2-Z-, --S(O).sub.2N(R.sup.6)C(O)-Z-,
--C(O)-Z- or a direct bond; [0287] each Z is independently a direct
bond or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; [0288]
each Y is independently selected from aryl-Z.sup.1-,
heterocyclyl-Z.sup.1-, C.sub.3-7cycloalkyl-Z.sup.1-,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl or
--(CH.sub.2).sub.1-4CH.sub.3-aF.sub.a; wherein each Y is
independently optionally substituted by up to 3 R.sup.4 groups;
[0289] each R.sup.4 is independently selected from halo,
--CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, --COOH, --C(O)OC.sub.1-6alkyl, OH or phenyl,
[0290] or R.sup.5--X.sup.1--, where X.sup.1 is independently as
defined in X above and R.sup.5 is selected from hydrogen,
C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, phenyl, naphthyl, heterocyclyl
or C.sub.3-7cycloalkyl; and R.sup.5 is optionally substituted by
halo, C.sub.1-6alkyl, --CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2,
COOH or C(O)OC.sub.1-6alkyl, [0291] wherein each phenyl, naphthyl
or heterocyclyl ring in R.sup.5 is optionally substituted by halo,
CH.sub.3-aF.sub.a, CN, NO.sub.2, NH.sub.2, C.sub.1-6alkyl,
--OC.sub.1-6alkyl, COOH, --C(O)OC.sub.1-6alkyl or OH; [0292] each
Z.sup.1 is independently a direct bond or a group of the formula
--(CH.sub.2).sub.p--C(R.sup.6).sub.2--(CH.sub.2).sub.q--; [0293]
R.sup.3 is selected from hydrogen or C.sub.1-6alkyl; and [0294]
R.sup.6 is independently selected from hydrogen, C.sub.1-6alkyl or
--C.sub.2-4alkyl-O--C.sub.1-4alkyl; [0295] each a is independently
1, 2 or 3; [0296] p is an integer between 0 and 2; [0297] q is an
integer between 0 and 2; [0298] and p+q<4.
[0299] According to a further feature of the second aspect of the
invention there is provided a method of combined treatment, in a
warm-blooded animal, of diabetes and obesity, comprising
administering a therapeutically effective amount of a compound of a
GLK activator, or a pharmaceutically-acceptable salt, pro-drug or
solvate thereof, wherein the GLK activator is a compound of Formula
(MV).
[0300] According to a further feature of the second aspect of the
invention there is provided a pharmaceutical composition comprising
a GLK activator, or a pharmaceutically acceptable salt, prodrug or
solvate thereof, in admixture with a pharmaceutically-acceptable
diluent or carrier for the combined treatment of diabetes and
obesity in a warm-blooded animal, wherein the GLK activator is a
compound of Formula (IV).
[0301] Further examples of GLK activators are contained in
International Application numbers: WO 00/58293, WO 01/44216, WO
01/83465, WO 01/83478, WO 01/85706, WO 01/85707, WO 02/08209 and WO
02/14312. The contents of aforesaid International Applications are
hereby incorporated by reference.
[0302] In a further feature of the second aspect of the invention
there is provided the use a GLK activator in the preparation of a
medicament for the treatment or prevention of diabetes and obesity,
wherein the GLK activator is a compound exemplified in aforesaid
International Applications or falls within the scope of aforesaid
International Applications.
[0303] According to a further feature of the second aspect of the
invention there is provided a method of combined treatment, in a
warm-blooded animal, of diabetes and obesity, comprising
administering a therapeutically effective amount of a compound of a
GLK activator, wherein the GLK activator is a compound exemplified
in aforesaid International Applications or falls within the scope
of aforesaid International Applications.
[0304] According to a further feature of the second aspect of the
invention there is provided a pharmaceutical composition comprising
a GLK activator, or a pharmaceutically acceptable salt, prodrug or
solvate thereof, in admixture with a pharmaceutically-acceptable
diluent or carrier for the combined treatment of diabetes and
obesity in a warm-blooded animal, wherein the GLK activator is a
compound exemplified in aforesaid International Applications or
falls within the scope of aforesaid International Applications.
[0305] The identification of compounds that are useful in the
combined treatment of diabetes and obesity is the subject of the
present invention. These properties may be assessed, for example,
by measuring changes in food intake, feeding-related behaviour (eg.
feeding, grooming, physical activity, rest) and body weight
separately or together with measuring plasma or blood glucose or
insulin concentrations with or without an oral glucose load/food in
a variety of animal models such as ob/ob mouse, db/db mouse, Fatty
Zucker rat, Zucker diabetic rat (ZDF), streptozotocin-treated rats
or mice or diet-induced obese mice or rats, as described in Sima
& Shafrir, 2001, Animal Models of Diabetes, A Primer (Harwood
Academic Publishers, Netherlands) or in animals treated with
glucose directly into the brain or in animals rendered diabetic by
treatment with streptozotocin and fed a high fat diet (Metabolism
49: 1390-4, 2000).
[0306] GLK activators may be used in the combined treatment of
diabetes and obesity alone or in combination with one or more
additional therapies. Such combination therapy may be achieved by
way of the simultaneous, sequential or separate administration of
the individual components of the treatment. Simultaneous treatment
may be in a single tablet or in separate tablets. Examples of
agents which may be used in combination therapy include those
listed in paragraphs 1)-11) above, as drugs which may be used with
compounds of Formula (I).
[0307] The following examples of Compounds of Formula (I)-(Ic) are
for illustration purposes and are not intended to limit the scope
of this application. Each exemplified compound represents a
particular and independent aspect of the invention. In the
following non-limiting Examples, unless otherwise stated:
[0308] (i) evaporations were carried out by rotary evaporation in
vacuo and work-up procedures were carried out after removal of
residual solids such as drying agents by filtration;
[0309] (ii) operations were carried out at room temperature, that
is in the range 18-25.degree. C. and under an atmosphere of an
inert gas such as argon or nitrogen;
[0310] (iii) yields are given for illustration only and are not
necessarily the maximum attainable;
[0311] (iv) the structures of the end-products of the Formula (I)
were confirmed by nuclear (generally proton) magnetic resonance
(NMR) and mass spectral techniques; proton magnetic resonance
chemical shift values were measured on the delta scale and peak
multiplicities are shown as follows: s, singlet; d, doublet; t,
triplet; m, multiplet; br, broad; q, quartet, quin, quintet;
[0312] (v) intermediates were not generally fully characterised and
purity was assessed by thin layer chromatography (TLC),
high-performance liquid chromatography (HPLC), infra-red (IR) or
NMR analysis;
[0313] (vi) chromatography was performed on silica (Merck Silica
gel 60, 0.040-0.063 mm, 230-400 mesh); and
[0314] (vi) Biotage cartridges refer to pre-packed silica
cartridges (from 40 g up to 400 g), eluted using a biotage pump and
fraction collector system; Biotage UK Ltd, Hertford, Herts, UK.
EXAMPLE A
Scheme 1: Preparation of 6-(E-3-phenoxy-phenyl]-vinyl)-nicotinic
acid
[0315] ##STR30## To a mixture of 6-methylnicotinate (151 mg, 1
mmol), acetic anhydride (541 mg, 5.3 mmol) and acetic acid (52 mg,
0.87 mmol) was added 3-(hydroxybenzyl)benzaldehyde (201 mg, 1.01
mmol). The reaction was heated to 120.degree. C. for 24 hours and
was then cooled to room temperature before ethyl acetate (5 ml) and
water (5 ml) were added. The biphasic mixture was separated and the
organic phase was washed with an aqueous saturated solution of
sodium bicarbonate (5 ml). The organic phase was then filtered
through magnesium sulfate absorbed onto silica gel and was
concentrated in vacuo. The crude product was chromatographed on
Kieselgel 60, eluting with a gradient of 10-40% ethyl acetate in
iso-hexane to give the product as a white solid (162 mg, 49%
yield); MS [M+H].sup.+ 332. The product from the previous step (162
mg) was dissolved in a mixture of THF (2.5 ml) and 1M aqueous NaOH
solution (1.25 ml) and was then heated for 2 hours at 60.degree. C.
The reaction was allowed to cool to room temperature overnight and
was then reduced in vacuo to remove the THF. 1N aqueous HCl was
added to precipitate out 6-(E-3-phenoxy-phenyl]-vinyl)-nicotinic
acid which was isolated by filtration as a white solid (117 mg, 76%
yield); H.sup.1 NMR .delta. (d.sup.6-DMSO) 6.95-7.85 (12H, m), 8.25
(1H, dd), 9.05 (1H, d), 13.30 (1H, br, s); MS [M+H].sup.+ 318.
EXAMPLE B
Scheme 2: Preparation of
6-(E-2-[-2-(4-isopropylbenzyloxy)-5-methylsulfanyl-phenyl]-vinyl)-nicotin-
ic acid
[0316] ##STR31## Sodium hydride (160 mg, 60% w/w in mineral oil, 4
mmol) was added to a solution containing 4-isopropylbenzyl chloride
(350 .mu.L, 2.1 mmol) and
6-[E-2-(-2-hydroxy-5-methylsulfanylphenyl)-vinyl]-nicotinic acid,
methyl ester (600 mg, 2 mmol) in DMF (20 mL). The mixture was
stirred overnight at room temperature. The reaction mixture was
concentrated in vacuo and the residue was dissolved in THF (10 mL).
Methanol (4 mL) and aqueous sodium hydroxide (4 mL, 1M) were added
and the solution was stirred at room temperature for 5 hours. The
reaction mixture was concentrated in vacuo before being dissolved
in water (10 mL). This solution was acidified with hydrochloric
acid (1M) and the resulting precipitate was isolated by filtration,
washed with water and dried in vacuo. The product was obtained as a
yellow solid (880 mg, quant.) .delta..sub.H (300 MHz, DMSO-d.sub.6)
13.2 (1H, s), 9.01 (1H, d), 8.22 (1H, dd), 8.04 (1H, d), 7.66 (1H,
d), 7.53 (1H, d), 7.45 (1H, d), 7.39 (2H, d), 7.29-7.20 (3H, m),
7.11 (1H, d), 5.18 (4H, s), 2.87 (1H, septet), 2.51 (3H and
residual DMSO-d.sub.5, s), and 1.19 (6H, d); m/z (LCMS) (FSI+) 420
(MH+); (ESI-) 418 (M-H).
EXAMPLE C
Scheme 2: Preparation of
6-[E-2-(-2-hydroxy-5-methylsulfanylphenyl)-vinyl]-nicotinic acid,
methyl ester
[0317] Sodium methoxide (2.29 g, 42.4 mmol) was added to a
suspension of
6-[E-2-(-2-acetoxy-5-methylsulfanylphenyl)-vinyl]-nicotinic acid,
methyl ester (13.26 g, 38.55 mmol) in methanol (200 mL). The
mixture was heated at 60.degree. C. for 3 hours. The reaction
mixture was concentrated in vacuo and water was added followed by
enough hydrochloric acid (1M) to acidify the solution. The
resultant precipitate was isolated by filtration, washed with water
and dried in vacuo. This procedure afforded the product as a yellow
solid (8.8 g, 76%) m/z (LCMS) (ESI+) 302 (MH+); (ESI-) 300
(M-H).
EXAMPLE D
Scheme 2: Preparation of
6-[E-2-(-2-acetoxy-5-methylsulfanylphenyl)-vinyl]-nicotinic acid,
methyl ester
[0318] 2-hydroxy-5-methylsulfanylbenzaldehyde (5.05 g, 30 mmol) was
dissolved in acetic anhydride (8 mL). Methyl 6-methylnicotinate
(4.54 g, 30 mmol) and acetic acid (1.7 mL, 30 mmol) were added. The
mixture was heated to 120.degree. C. and stirred for 18 hours. The
mixture was allowed to cool to room temperature before being poured
into water (200 mL). The aqueous mixture was extracted with ethyl
acetate (200 mL). The extract was washed with brine, dried over
magnesium sulfate and concentrated in vacuo to afford a brown
solid. This material was triturated with ethanol to give
6-[E-2-(-2-acetoxy-5-methylsulfanylphenyl)-vinyl]-nicotinic acid,
methyl ester as a colourless solid (7.33 g, 71%) .delta..sub.H (300
MHz, DMSO-d.sub.6) 9.06 (1H, d), 8.28 (1H, dd), 7.77-7.68 (3H, m),
7.50 (1H, d), 7.27 (1H, d), 7.15 (1H, d), 3.86 (3H, s), 2.55 (3H,
s), and 2.36 (3H, s); m/Z (ESI+) 344 (MH+).
EXAMPLE E
Scheme 3: Preparation of
[0319] ##STR32## Compound (a) (260 mg 0.69 mm) was stirred with
potassium carbonate (286 mg 2.07 mm), potassium iodide (catalytic)
and 2-methylbenzyl bromide (0.101 ml 0.76 mm) in dimethylformamide
at 60.degree. C. overnight. ##STR33## Water (5 ml) was added to the
cooled reaction and the mixture was filtered, washed well with
water and dried under vacuum at room temperature. The compound was
purified by bond elute chromatography, eluting with 20% ethyl
acetate/isohexane. The product from this column was stirred with 2N
sodium hydroxide (1.725 ml 3.45 mm) in tetrahydrofuran (4 ml)
methyl alcohol (2 ml) and water (2 ml) for 3 hours at room
temperature. The mixture was then evaporated to dryness, diluted
with water and acidified with 2N hydrochloric acid to give a
precipitate. The precipitate was filtered off, washed well with
water and dried at room temperature under vacuum to give the
product. (270 mg 83.4%) Nmr dmso-d.sub.6 (d) 2.34 (3H s), 5.11-5.23
(4H d) 6.72 (1H s) 7.05 (2H s) 7.15-7.35 (5H m) 7.4-7.5 (3H m)
7.55-7.65 (2H m) 7.68-7.78 (1H d) 8.18-8.23 (1H d) 9.03 (1H s) M.S.
MH.sup.+ 470.
EXAMPLE F
Scheme 3: Preparation of
[0320] ##STR34## Compound (b) (9.65 g 35.61 mm) was stirred with
2-fluorobenzyl bromide (4.29 ml 35.61 mm), potassium carbonate
(14.74 g 106.83 mm) potassium iodide (11.0 g 6 mm catalytic) in
dimethylformamide (40 ml). ##STR35## After cooling, the mixture was
poured into water and extracted into ethyl acetate. The combined
organic extracts were dried over magnesium sulphate, filtered and
evaporated to give the crude product. Chromatography on silica
using 0.6% methanol/methylene chloride, followed by 10%
methanol/methylene chloride gave the pure product (1.89 g 14%).
M.S. MH.sup.+ 380.
EXAMPLE G
Scheme 3: Preparation of
[0321] ##STR36## The diacetyl derivative (15.36 g 43 mm) of the
structure above was stirred at room temperature with 4N sodium
methoxide (9.8 ml 43 mm) in tetrahydrofuran (10 ml) and methanol
(10 ml) for 1 hour. The mixture was evaporated diluted with water
and acidified with hydrochloric acid The resulting precipitate was
filtered off washed with water and vacuum dried at 50.degree. C. to
give the product (11.2 g 96.1%) MS MH.sup.+ 272
EXAMPLE H
Scheme 3: Preparation of
[0322] ##STR37## 3,5-Dihydroxybenzaldehyde (10.0 g 72.46 mm) was
stirred with 6-methyl methyl nicotinate (10.94 g 72.46 mm) in
acetic acid (3.7 ml 65 mm) and acetic anhydride (37 ml 0.39 m) at
120.degree. C. overnight. On cooling the brown solid mixture was
diluted with ethyl acetate The insoluble material was filtered off
and washed with ethyl acetate to give the product (15.36 g) The
remaining organic solubles were washed with water then added to
sodium bicarbonate and the solid filtered off washed with water and
vacuum dried (1.78 g). Both the solids were identical and so were
combined to give the final product (17.14 g 66.6%) MS MH.sup.+
356.
EXAMPLE I
Scheme 4: Preparation of
6-(E-2-[-2-(2-benzyloxy)-5-methylsulfanyl-phenyl]-vinyl)-nicotinic
acid, methyl sulphonamide
[0323] To a suspension of Compound (c) (100 mg) in dichloromethane
(10 ml) was added methanesulfonamide (38 mg),
4-dimethylaminopyridine (130 mg), then
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (102
mg). The mixture was stirred for 20 hours at ambient temperature.
Diluted with dichloromethane (20 ml), washed with 2M hydrochloric
acid (10 ml), brine (15 ml), and dried over Magnesium sulfate.
Volatile material was removed by evaporation to give the title
product (112 mg), as a solid. .sup.1HNMR (CDCl.sub.3) 2.48 (s, 3H),
3.43 (s, 3H), 5.20 (s, 2H), 6.92 (d, 1H), 7.25 (m, 1H+ CDCl.sub.3),
7.33-7.48 (m, 7H), 7.57 (d, 1H), 7.60 (s, 1H), 8.13 (d, 1H), 8.32
(d, 1H), 9.26 (s, 1H). MS ES.sup.+ 455.13 (M+H).sup.+.
##STR38##
EXAMPLE J
[0324] By analagous methods to those described compounds
J.sub.1-127 listed in Table 1 were also made. Table 2 gives the
parent molecular weight, mass spec data and the synthetic scheme
for the compounds listed in Table 1. ##STR39##
[0325] In compounds 1-114 R.sup.3 is OH; in compounds 115-123
R.sup.3 is methoxy; in compound 124 R.sup.3 is
methylsulphonylamino; in compound 125 R.sup.3 is methoxyamino; in
compounds 126-127 R.sup.3 is 2-hydroxyethylamide.
[0326] Compound 2 corresponds to the product of Example A. Compound
36 corresponds to the product of Example B. Compound 101
corresponds to Example E. Compound 124 corresponds to the product
of Example I. TABLE-US-00001 TABLE 1 Compound number 2 3 4 5 1 H
Methylthio H H 2 H Phenoxy H H 3 H CF.sub.3 H CF3 4 H Benxyloxy H H
5 OH Br H Br 6 4-ChloroPhenylthio H H NO2 7 4-MethylPhenylthio H H
NO2 8 Chloro H H Ethoxy 9 Chloro H H Chloro 10 Chloro H H CF3 11 H
H (5-t-Butyl)- H thiazol-2-yl 12 H (4-t-Butyl)-Phenoxy H H 13 Bromo
H H OMe 14 Bromo H H OEt 15 1-morpholino H H NO2 16
3-Trifluoromethyl- H H NO2 phenoxy 17 methoxy H H SMe 18
4-Fluorobenzyloxy H H SMe 19 4- H H SMe Methoxybenzyloxy 20 OH H H
SMe 21 OH H H OMe 22 Allyloxy H H SMe 23 Cyclopropyl H H SMe
methoxy 24 O-3-Pentyl H H SMe 25 benzyloxy H H OMe 26 Benzyloxy H H
SMe 27 H 4-Fluorophenyl H H 28 H 4-Chlorophenoxy H H 29 H OMe H OMe
30 H 4-Methoxyphenoxy H H 31 Fluoro H H Trifluoromethyl 32
4-ChloroPhenylthio H H H 33 3- H H SMe Carboxybenzyloxy 34 4- H H
SMe Carboxybenzyloxy 35 3-Nitrobenzyloxy H H SMe 36 4- H H SMe
Isopropylbenzyloxy 37 4-Methylsulphonyl- H H SMe benzyloxy 38 3,5-
H H SMe Difluorobenzyloxy 39 4-Vinylbenzyloxy H H SMe 40 2,4- H H
SMe Difluorobenzyloxy 41 3-Trifluoromethyl- H H SMe
4-fluorobenzyloxy 42 3-Trifluoromethyl- H H SMe benzyloxy 43 3,4- H
H SMe Methylenedioxy- benzyloxy 44 3-Fluorobenzyloxy H H SMe 45
2-Methylbenzyloxy H H SMe 46 3-Methylbenzyloxy H H SMe 47
2-Fluorobenzyloxy H H SMe 48 4-Bromobenzyloxy H H SMe 49
4-Methylbenzyloxy H H SMe 50 3- H H SMe Methoxybenzyloxy 51 3,4- H
H SMe Difluorobenzyloxy 52 3- H H H Carboxybenzyloxy 53 3,5- H H H
Difluorobenzyloxy 54 2- H H H Cyanoobenzyloxy 55 2-Methylbenzyloxy
H H H 56 2,4- H H H Difluorobenzyloxy 57 3-Trifluoromethyl- H H H
benzyloxy 58 2,5- H H H Difluorobenzyloxy 59 3,4- H H H
Methylenedioxy- benzyloxy 60 3-Fluorobenzyloxy H H H 61
2-Fluorobenzyloxy H H H 62 4-Fluorobenzyloxy H H H 63 3- H H H
Methoxybenzyloxy 64 3-Phenylallyloxy H H SMe 65 3-Phenylpropoxy H H
SMe 66 Cyclohexyl- H H SMe methoxy 67 2-N- H H SMe
Methylpyrrolidino- 2-Ethoxy 68 2-(4- H H SMe Bromophenoxy)- ethoxy
69 2-Hydroxy-2- H H SMe Trifluoromethyl- ethoxy 70 4-(3,5- H H SMe
dimethylisoxozolo)- methoxy 71 2-(2-1,3-diazolo)- H H SMe ethoxy 72
2-Carboxyfurano- H H SMe methoxy 73 H 2-Chlorobenzyloxy H H 74
Benzyloxy H H 2-Methoxy- ethoxy 75 2-Methylbenzyloxy H H 2-Methoxy-
ethoxy 76 Benzyloxy H H Trifluoromethoxy 77 3-Methylbenzyloxy H H
Trifluoromethoxy 78 Hydroxy H H t-Butyl 79 3-(5- H H SMe
methyl)isoxazolo- methoxy 80 2-Furanomethoxy H H SMe 81
3-Pyridomethoxy H H SMe 82 2- H H SMe Thiophenomethoxy 83 3- H H
SMe Thiophenomethoxy 84 Benzyloxy H H 2-Cyanobenzyloxy 85 4- H H
SMe Phenylcarbamoyl- benzyloxy 86 4-Carbamoyl- H H SMe benzyloxy 87
4-benzoyl- H H SMe benzyloxy 88 4-Sulphamoyl- H H SMe benzyloxy 89
4-Carboxymethyl- H H SMe benzyloxy 90 4-(2- H H SMe Methylcarboxy)-
phenylbenzyloxy 91 4- H H SMe Carboxymethoxy- benzyloxy 92
4-Cyanobenzyloxy H H SMe 93 4-Nitrobenzyloxy H H SMe 94 H
2-Cyanobenzyloxy H 2-Cyanobenzyloxy 95 H 2-Fluorobenzyloxy H
2-Fluorobenzyloxy 96 H 2-Chlorobenzyloxy H 2-Chlorobenzyloxy 97 H
3-(5-methyl)isoxazolyl- H 3-(5- methoxy methyl)- isoxazolyl-
methoxy 98 H 2-[2-methylthiazol-4-yl] H 2-[4-(2- ethoxy methyl)-
thiazolyl]- ethoxy 99 H Benzyloxy H 2-Fluorobenzyloxy 100 H
2-chlorobenzyloxy H 2-Fluorobenzyloxy 101 H 2-Methylbenzyloxy H
2-Fluorobenzyloxy 102 H 2-Cyanobenzyloxy H 2-Fluorobenzyloxy 103 H
2-Trifluoromethyl- H 2-Fluorobenzyloxy benzyloxy 104 H
2-Trifluoromethoxy- H 2-Fluorobenzyloxy benzyloxy 105 H
2-Methoxybenzyloxy H 2-Fluorobenzyloxy 106 H
2-[2-methylthiazol-4-yl] H Isopropoxy ethoxy 107 H 2-[2- H
2-Pyridyl- methylthiazol-4-yl]ethoxy methoxy 108 H
5-methylisoxazol-3-yl- H Isopropoxy methoxy 109 H
5-methylisoxazol-3-yl- H 2-Methylbenzyloxy methoxy 110 H
5-methylisoxazol-3-yl- H 4-(2- methoxy methyl)- thiazolyl- methoxy
111 H 2-[4-methylthiazol-5-yl] H 2-Methylbenzyloxy ethoxy 112 H
2-[4- H 3-(5- methylthiazol-5-yl]- methyl)- ethoxy isoxazolyl-
methoxy 113 4- H H Methyl- Isopropylbenzyloxy sulphoxy 114
Benzyloxy H H Methylsulphonyl 115 Ethylthio Methoxy H H 116 Hydroxy
H H Methylthio 117 H 2-chlorobenzyloxy H H 118 H 2-[4- H Isopropoxy
methylthiazol-5-yl]- ethoxy 119 H 2-[4- H 2-Pyridyl-
methylthiazol-5-yl]- methoxy ethoxy 120 H 5-methylisoxazol-3-yl- H
Isopropoxy methoxy 121 H 5-methylisoxazol-3-yl- H 2-Methylbenzyloxy
methoxy 122 H 5-methylisoxazol-3-yl- H 2-[4-(2- methoxy methyl)-
thiazolyl]- ethoxy 123 H 2-[4- H 2-Methylbenzyloxy
methylthiazol-5-yl]- ethoxy 124 Benzyloxy H H Methylthio 125
Benzyloxy H H Methylthio 126 Benzyloxy H H Bromo 127 Benzyloxy H H
Methylthio
[0327] TABLE-US-00002 TABLE 2 Parent Compound Molecular Mass Spec
Synthetic Number Weight (+ve/-ve) scheme 1 271.34 272, 1 2 317.35
318, 1 3 361.25 362, 1 4 331.37 332, 1 5 399.04 398, 400, 402, 1 6
412.85 411, 413 1 7 392.44 391, 393 1 8 303.75 302, 304 1 9 294.14
295, 293 1 10 327.69 326, 328 1 11 364.47 365, 363 1 12 373.46 374,
372 1 13 334.17 334, 336 1 14 348.2 348, 350 1 15 355.35 354, 356 1
16 430.34 431, 1 17 301.37 302, 300 2 18 395.46 396, 394 2 19
407.49 408, 406 2 20 287.34 288, 286 2 21 271.28 272, 270 2 22
327.41 328, 2 23 341.43 342, 2 24 357.48 358, 2 25 361.4 362, 360 2
26 377.47 378, 376 2 27 319.34 320, 318 2 28 351.79 352, 350 2 29
285.3 286, 284 2 30 347.37 348, 346 2 31 311.24 312, 310 2 32
367.86 368, 366 2 33 421.48 422, 2 34 421.48 422, 420 2 35 422.46
423, 421 2 36 419.55 420, 418 2 37 455.56 456, 454 2 38 413.45 414,
412 2 39 403.5 404, 402 2 40 413.45 414, 412 2 41 463.45 464, 462 2
42 445.46 446, 444 2 43 421.48 422, 420 2 44 395.46 396, 394 2 45
391.49 392, 390 2 46 391.49 392, 390 2 47 395.46 396, 394 2 48
456.36 456, 458, 454, 2 456 49 391.49 392, 390 2 50 407.49 408, 406
2 51 413.45 414, 412 2 52 375.38 376, 374 2 53 367.36 368, 366 2 54
356.38 357, 355 2 55 345.4 346, 344 2 56 367.36 368, 366 2 57
399.37 400, 398 2 58 367.36 368, 366 2 59 375.38 376, 374 2 60
349.36 350, 348 2 61 349.36 350, 348 2 62 349.36 350, 348 2 63
361.4 362, 360 2 64 403.5 404, 402 2 65 405.52 406, 404 2 66 383.51
384, 382 2 67 398.53 399, 397 2 68 486.39 486, 488, 484, 2 486 69
399.39 400, 398 2 70 396.47 397, 395 2 71 387.46 388, 386 2 72
411.44 412, 410 2 73 365.82 366, 2 74 405.45 406 2 75 419.48 420 2
76 415.37 416 2 77 429.4 430 2 78 297.36 298, 296 2 79 382.44 383,
2 80 367.43 368, 2 81 378.45 379, 2 82 383.49 384, 2 83 383.49 384,
2 84 462.51 463 2 85 496.59 497 2 86 420.49 421 2 87 481.57 482 2
88 456.54 457 2 89 435.5 436 2 90 511.6 512 2 91 451.5 452 2 92
402.48 403 2 93 422.46 423 2 94 487.52 488 2 95 473.48 474, 2 96
506.39 506, 2 97 447.45 448, 446 2 98 507.63 508, 2 99 455.49 456,
454 3 100 489.94 490, 492, 488, 3 490 101 469.52 470, 68 3 102
480.5 481, 479 3 103 523.49 524, 522 3 104 539.49 540, 538 3 105
485.52 486, 484 3 106 424.52 425, 423 3 107 473.55 474, 472 3 108
394.43 395, 393 3 109 456.5 457, 455 3 110 463.52 464, 462 3 111
486.59 487, 485 3 112 477.54 478, 476 3 113 435.55 434, 436 5 114
409.464 , 408 5 115 329.42 330, 1 116 301.37 302, 300 2 117 379.85
380, 2 118 438.55 439, 3 119 487.58 488, 3 120 408.46 409, 3 121
470.53 471, 469 3 122 477.54 478, 476 3 123 500.62 501, 499 3 124
454.57 455.13 4 125 406.51 407.12 4 126 453.339 453, 4 127 420.534
421, 4
EXAMPLE K
Scheme 5: Preparation of
6-(E-2-[-2-(2-benzyloxy)-5-methylsulfanyl-phenyl]-vinyl)-nicotinic
acid, N-methoxyamide
[0328] ##STR40## To a stirred suspension of
6-{(E)-2-[2-(benzyloxy)-5-(methylthio)phenyl]ethenyl}nicotinic acid
(82 mg, 0.22 mmol) in DCM (10 ml) was added oxalyl chloride (35 mg,
0.28 mmol) and DMF (catalytic amount). The mixture was stirred at
ambient temperature for 17 hours, and volatile material removed by
evaporation to give a gum which was then suspended in DCM (10 ml).
Methoxyamine hydrochloride (37 mg, 0.44 mmol) and triethylamine
(0.06 ml, 0.43 mmol) were added to the suspension and the resulting
solution stirred at ambient temperature for 4 hours. It was then
diluted with DCM (20 ml) and washed sequentially with 2M
hydrochloric acid (20 ml), brine (20 ml), and dried over
MgSO.sub.4. Volatile material was removed by evaporation to leave a
gum which was purified by flash chromatography on silica, eluting
with 1-2% methanol in DCM to give an oil. Triturated with diethyl
ether gave
6-(E-2-[-2-(2-benzyloxy)-5-methylsulfanyl-phenyl]-vinyl)-nicotinic
acid, N-methoxyamide (33 mg) as a solid, NMR: .delta..sub.H (300
MHz, DMSO-d.sub.6) 2.48 (s, 3H+DMSO), 3.72 (s, 3H), 5.22 (s, 2H),
7.11 (d, 1H), 7.24 (s, 1H), 7.30-7.53 (m, 7H), 7.68 (s, 1H), 8.05
(m, 2H), 8.88 (s, 1H), 11.82 (s, 1H); m/z 407 (M+H).sup.+.
EXAMPLE L
Scheme 6: Preparation of
6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)-pyridine-3-oxyacetic
acid
[0329] ##STR41## To a stirred solution of
6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)-pyridine-3-oxyacetic
acid t-butyl ester (100 mg, 0.19 mmol) in dichloromethane (2 ml)
was added trifluoroacetic acid (1 ml). The solution was stirred at
ambient temperature for 6 hours. Volatile material was removed by
evaporation, and the residue azeotroped with toluene to give an
oil. This was triturated under diethyl ether to give the title
compound (72 mg) as a solid, NMR: 8H (300 MHz, DMSO-d.sub.6) 4.80
(s, 2H), 5.12 (s, 4H), 6.60 (s, 1H), 6.89 (s, 2H), 7.08-7.60 (m,
14H), 8.31 (s, 1H), m/z 468 (M+H).sup.+. The requisite t-butyl
ester starting material was prepared as follows: ##STR42## To a
suspension of
3-hydroxy-6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)pyridine (150
mg) in anhydrous THF (10 ml) was added sodium hydride (30 mg) at
ambient temperature, under an atmosphere of nitrogen. The reaction
was allowed to stir for 20 minutes and then t-butyl bromo acetate
(0.06 ml) was added. The reaction was stirred for 30 minutes before
being cooled to 0.degree. C. and DMF (3 ml) added. The reaction was
then allowed to warm to ambient temperature, when water (20 ml) was
added. The aqueous was extracted with ethyl acetate (3.times.20 ml)
and the extracts combined, dried (MgSO.sub.4) and evaporated to
leave an oil. This was purified by flash chromatography on a 10 g
silica Bondelut, to give an oil which was triturated under diethyl
ether:hexane (1:1) to give
6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)-pyridine-3-oxyacetic
acid t-butyl ester (135 mg) as a solid, MS m/z 524 (M+H).sup.+. The
requisite 3-hydroxy pyridine starting material was prepared as
follows: ##STR43## To a suspension of
3-acetoxy-6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)pyridine (100
mg) in methanol (2 ml) was added sodium hydroxide (0.44 ml, 0.86
mmol), and the mixture stirred at ambient temperature for 1.5
hours. An excess of 2M hydrochloric acid was added. A precipitate
formed, which was filtered off, washed sequentially with water and
ether, and dried under vacuum at 60.degree. C. for 5 hours, to give
3-hydroxy-6-(E-2-[-2-(3,5-dibenzyloxy)-phenyl]-vinyl)pyridine (82
mg) as a solid, m/z 410 (M+H).sup.+. The requisite 3-acetoxy
pyridine starting material was prepared as follows: ##STR44## To a
stirred solution of
6-{2-[3,5-bis(benzyloxy)phenyl]-2-hydroxyethyl}pyridin-3-ol (105
mg) in acetic anhydride (0.23 ml) was added acetic acid (0.23 ml);
the mixture was heated to 120.degree. C. and stirred for 17 hours.
It was then allowed to cool to ambient temperature and water (10
ml) was added, followed by extraction with ethyl acetate
(3.times.20 ml). The extracts were combined, dried (MgSO.sub.4) and
evaporated to give an oil, which was triturated under hexane to
give the title compound (80 mg) as a solid. MS ES+ 452 (M+H).sup.+.
The requisite
6-{2-[3,5-bis(benzyloxy)phenyl]-2-hydroxyethyl}pyridin-3-ol
starting material was prepared as follows: ##STR45## To a stirred
solution of 5-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpyridine
(1.20 g) in anhydrous THF (15 ml) under nitrogen and at -78.degree.
C. was added LDA (3.22 ml), and the solution stirred at -78.degree.
C. for 1 hour. 3,5 dibenzyloxy-benzaldehyde (2.05 g) was then added
dropwise as a solution in THF, and the reaction mixture allowed to
warm to ambient temperature over 1 hour. Water (20 ml) was added
and the resulting mixture extracted with ethyl acetate (3.times.30
ml). The extracts were combined, washed with brine (20 ml), dried
(MgSO.sub.4) and evaporated to give a gum. This was dissolved in
THF (10 ml) and concentrated hydrochloric acid (10 ml) added. The
mixture was stirred at ambient temperature for 3 hours, cooled to
0.degree. C. and taken to pH 8.5 with concentrated ammonia
solution. The mixture was diluted with water (50 ml) and extracted
with ethyl acetate (3.times.100 ml). The extracts were combined,
dried (MgSO.sub.4) and evaporated to leave an oil which was
purified by MPLC on silica, eluting with 60-100% ethyl acetate in
hexane to give
6-{2-[3,5-bis(benzyloxy)phenyl]-2-hydroxyethyl}pyridin-3-ol (2.25
g) as a glass, m/z 428 (M+H).sup.+.
EXAMPLE M
Scheme 7: Preparation of E
2-{-2-[3,5-di-(2-chlorobenzyloxy)]-phenyl}-vinyl-thiazole-4-carboxylic
acid
[0330] ##STR46## This was prepared from E
2-{-2-[3,5-di-(2-chlorobenzyloxy)]-phenyl}-vinyl-thiazole-4-carboxylic
acid ethyl ester by alkaline hydrolysis in a manner similar to that
described in Example A, Scheme 1. The requisite ethyl ester
starting material was prepared as follows: ##STR47## Ethyl
2-[(diethoxyphophoryl)methyl]-1,3-thiazole-4-carboxylate (280 mgs,
0.91 mmol) in dry tetrahydrofuran (10 ml) was added to a stirred
suspension of sodium hydride (40 mgs of 60% dispersion, 1 mmol) in
dry tetrahydrofuran (10 ml). After stirring for half an hour at
room temperature a solution of 3,5 bis(2-chlorobenzyl)benzaldehyde
(420 mgs 1.09 mmol) in dry tetrahydrofuran (10 ml) was added
slowly. The mixture was stirred at ambient temperature for 4 hours,
quenched with water and acidified with 2M aq hydrochloric acid. The
mixture was extracted with ethyl acetate and the extract combined,
dried (MgSO.sub.4) and evaporated to leave a gum. Chromatography on
silica, eluting with 20% EtOAc in hexane, gave E
2-{-2-[3,5-di-(2-chlorobenzyloxy)]-phenyl}-vinyl-thiazole-4-carboxylic
acid ethyl ester (260 mgs), NMR: .delta..sub.H (300 MHz,
DMSO-d.sub.6): 1.25-1.35(3H, t); 4.25-4.35 (2H, q); 5.2 (4H, s);
6.69 (1H, s); 7.08 (2H, s); 7.34-7.45 (4H, m); 7.45-7.55 (3H, m);
7.55-7.65 (3H, m); 8.45 (1H, m). The requisite ethyl
2-[(diethoxyphophoryl)methyl]-1,3-thiazole-4-carboxylate starting
material was prepared as follows: ##STR48## Ethyl
2-(bromomethyl)-1,3-thiazole-5-carboxylate (460 mgs, 1.85 mmol) in
dry tetrahydrofuran (2.5 ml) was added dropwise to
triethylphosphite (2.5 ml, 2.46 g, 14.8 mmol) under argon at a
temperature of 105.degree. C. On completion of the addition the
mixture was warmed to 140.degree. C. at which it was maintained for
one hour. The triethylphosphite was then removed under reduced
pressure and the resultant material chromatographed (silica,
EtOAc/hexane) to give ethyl
2-[(diethoxyphophoryl)methyl]-1,3-thiazole-4-carboxylate (300 mgs),
NMR: .delta..sub.H (300 MHz, DMSO-d.sub.6):1.15-1.35 (9H, m);
3.95-4.12 (4H, m); 4.22-4.35 (2H, q); 8.43 (1H, s). The requisite
ethyl 2-(bromomethyl)-1,3-thiazole-5-carboxylate starting material
was prepared as follows: ##STR49## N-Bromosuccinimide (0.91 g, 5.1
mmol) was added to a solution of ethyl
2-methyl-thiazole-5-carboxylate (0.8 g, 4.7 mmol) in carbon
tetrachloride. The resultant reaction mixture was stirred for one
hour whilst being illuminated by a photoflood lamp. After removing
the solvent from the reaction mixture the resultant material was
partitioned between ethyl acetate and water. The organic phase was
then separated off, dried (MgSO.sub.4) and the evaporated.
Chromatography on silica, eluting with 30% ethyl acetate in hexane,
gave ethyl 2-(bromomethyl)-1,3-thiazole-5-carboxylate (490 mgs),
NMR: .delta..sub.H (300 MHz, DMSO-d.sub.6: 1.20-1.38 (3H, t);
4.20-4.37 (2H, q); 5.05 (2H, s); 8.55 (1H, s).
EXAMPLE N
[0331] By analogous methods to those described compounds N.sub.1-8
listed in Table 3 were also made. TABLE-US-00003 TABLE 2 Route No
Structure (Example) MS NMR 1 ##STR50## I 455 .delta..sub.H (300
MHz, CDCl.sub.3) 2.48 (s, 3H), 3.43(s, 3H), 5.20 (s, 2H), 6.92(d,
1H), 7.25 (s, CHCl.sub.3+1H), 7.33-7.48 (m, 7H), 7.57(d, 1H), 7.60
(s, 1H), 8.13(d, 1H), 8.32 (d, 1H), 9.26(s, 1H). 2 ##STR51## K
Scheme 5 407 .delta..sub.H (300 MHz, DMSO-d.sub.6) 2.48(s,
3H+DMSO), 3.72 (s, 3H), 5.22(s, 2H), 7.11 (d, 1H), 7.24(s, 1H),
7.30-7.53(m, 7H), 7.68(s, 1H), 8.05(m, 2H), 8.88(s, 1H), 11.82(s,
1H). 3 ##STR52## A Scheme 1 373 .delta..sub.H (300 MHz,
DMSO-d.sub.6) 1.2(s, 9H), 7.0(d, 3H), 7.4 (m, 6H), 7.8(d, 1H), 8.7
(s, 1H), 9.1(s, 1H). 4 ##STR53## L Scheme 6 468 .delta..sub.H (300
MHz, DMSO-d.sub.6) 4.80(s, 2H), 5.12(s, 4H), 6.60(s, 1H), 6.89(s,
2H), 7.08-7.60(m, 14H), 8.31 (s, 1H). 5 ##STR54## A Scheme 1*
.delta..sub.H (300 MHz, DMSO-d.sub.6) 5.21(4H, s), 6.72(1H, s),
7.10(2H, app s), 7.30-7.44(5H, m), 7.44-7.55 (2H, m), 7.55-7.65(2,
m), 7.90-8.1(1H, d), 9.14 (2H, s). 6 ##STR55## M Scheme 7 (by
analogy with Example 8) .delta..sub.H (300 MHz, DMSO-d.sub.6)
5.20(4H, s), 6.62(1H, s), 6.71(1H, d), 6.97(2H, d), 7.14(1H, d),
7.26(2H, m), 7.40(4H, m), 7.52(2H, m), 7.63(2H, m). 7 ##STR56## M
Scheme 7 (by analogy with Example 8) 512 514 .delta..sub.H (300
MHz, DMSO-d.sub.6), 5.19(4H, s), 6.68(1H, s), 7.01(2H, s),
7.31-7.45(5, m), 7.45-7.58(.about.2.5H, m), 7.58-7.69(.about.2.5H,
m), 7.87 (1H, s) 8 ##STR57## M Scheme 7** (described) 512
.delta..sub.H (300 MHz, DMSO-d.sub.6), 5.19(4H, s), 6.72(1H, s),
7.08(2H, s), 7.30-7.45 (4H, m), 7.45-7.55(2H, m), 7.55-7.68(4H, m),
8.33 (1H, s) *Example 5 - starting material (ethyl 2-methyl
pyrimidine-5-carboxylate) prepared according to J Het Chem 27 295
(1990). **Ethyl 2 methyl-1,3-thiazole-5-carboxylate prepared as
described in J. Am. Chem. Soc. 1982, 104, 4461-4465
The compounds A-I, J.sub.1-127, K, L, M and N.sub.1-8 were found to
have an activity of at least 40% activity at 10 .mu.m when tested
in the GLK/GLKRP scintillation proximity assay described below.
Biological Tests: The biological effects of the compounds of the
invention may be tested in the following way:
[0332] (1) Enzymatic activity of GLK may be measured by incubating
GLK, ATP and glucose. The rate of product formation may be
determined by coupling the assay to a G-6-P dehydrogenase,
NADP/NADPH system and measuring the increase in optical density at
340 nm (Matschinsky et al 1993).
[0333] (2) A GLK/GLKRP binding assay for measuring the binding
interactions between GLK and GLKRP. The method may be used to
identify compounds which modulate GLK by modulating the interaction
between GLK and GLKRP. GLKRP and GLK are incubated with an
inhibitory concentration of F-6-P, optionally in the presence of
test compound, and the extent of interaction between GLK and GLKRP
is measured. Compounds which either displace F-6-P or in some other
way reduce the GLK/GLKRP interaction will be detected by a decrease
in the amount of GLK/GLKRP complex formed. Compounds which promote
F-6-P binding or in some other way enhance the GLK/GLKRP
interaction will be detected by an increase in the amount of
GLK/GLKRP complex formed. A specific example of such a binding
assay is described below
GLK/GLKRP Scintillation Proximity Assay
[0334] Recombinant human GLK and GLKRP were used to develop a "mix
and measure" 96 well SPA (scintillation proximity assay). (A
schematic representation of the assay is given in FIG. 3). GLK
(Biotinylated) and GLKRP are incubated with streptavidin linked SPA
beads (Amersham) in the presence of an inhibitory concentration of
radiolabelled [3H]F-6-P (Amersham Custom Synthesis TRQ8689), giving
a signal as depicted in FIG. 3. Compounds which either displace the
F-6-P or in some other way disrupt the GLK/GLKRP binding
interaction will cause this signal to be lost.
[0335] Binding assays were performed at room temperature for 2
hours. The reaction mixtures contained 50 mM Tris-HCl (pH=7.5), 2
mM ATP, 5 mM MgCl.sub.2, 0.5 mM DTT, recombinant biotinylated GLK
(0.1 mg), recombinant GLKRP (0.1 mg), 0.05 mCi [3H] F-6-P
(Amersham) to give a final volume of 100 ml. Following incubation,
the extent of GLK/GLKRP complex formation was determined by
addition of 0.1 mg/well avidin linked SPA beads (Amersham) and
scintillation counting on a Packard TopCount NXT.
[0336] The exemplified compounds described above were found to have
an activity of at least 40% activity at 10 .mu.m when tested in the
GLK/GLKRP scintillation proximity assay.
[0337] (3) A F-6-P/GLKRP binding assay for measuring the binding
interaction between GLKRP and F-6-P. This method may be used to
provide further information on the mechanism of action of the
compounds. Compounds identified in the GLK/GLKRP binding assay may
modulate the interaction of GLK and GLKRP either by displacing
F-6-P or by modifying the GLK/GLKRP interaction in some other way.
For example, protein-protein interactions are generally known to
occur by interactions through multiple binding sites. It is thus
possible that a compound which modifies the interaction between GLK
and GLKRP could act by binding to one or more of several different
binding sites.
[0338] The F-6-P/GLKRP binding assay identifies only those
compounds which modulate the interaction of GLK and GLKRP by
displacing F-6-P from its binding site on GLKRP.
[0339] GLKRP is incubated with test compound and an inhibitory
concentration of F-6-P, in the absence of GLK, and the extent of
interaction between F-6-P and GLKRP is measured. Compounds which
displace the binding of F-6-P to GLKRP may be detected by a change
in the amount of GLKRP/F-6-P complex formed. A specific example of
such a binding assay is described below
F-6-P/GLKRP Scintillation Proximity Assay
[0340] Recombinant human GLKRP was used to develop a "mix and
measure" 96 well scintillation proximity assay. (A schematic
representation of the assay is given in FIG. 4). FLAG-tagged GLKRP
is incubated with protein A coated SPA beads (Amersham) and an
anti-FLAG antibody in the presence of an inhibitory concentration
of radiolabelled [3H]F-6-P. A signal is generated as depicted in
FIG. 4. Compounds which displace the F-6-P will cause this signal
to be lost. A combination of this assay and the GLK/GLKRP binding
assay will allow the observer to identify compounds which disrupt
the GLK/GLKRP binding interaction by displacing F-6-P.
[0341] Binding assays were performed at room temperature for 2
hours. The reaction mixtures contained 50 mM Tris-HCl (pH=7.5), 2
mM ATP, 5 mM MgCl.sub.2, 0.5 mM DTT, recombinant FLAG tagged GLKRP
(0.1 mg), Anti-Flag M2 Antibody (0.2 mg) (IBI Kodak), 0.05 mCi [3H]
F-6-P (Amersham) to give a final volume of 100 ml. Following
incubation, the extent of F-6-P/GLKRP complex formation was
determined by addition of 0.1 mg/well protein A linked SPA beads
(Amersham) and scintillation counting on a Packard TopCount
NXT.
Production of Recombinant GLK and GLKRP:
Preparation of mRNA
[0342] Human liver total mRNA was prepared by polytron
homogenisation in 4M guanidine isothiocyanate, 2.5 mM citrate, 0.5%
Sarkosyl, 100 mM b-mercaptoethanol, followed by centrifugation
through 5.7M CsCl, 25 mM sodium acetate at 135,000 g (max) as
described in Sambrook J, Fritsch E F & Maniatis T, 1989.
[0343] Poly A.sup.+ mRNA was prepared directly using a
FastTrack.TM. mRNA isolation kit (Invitrogen).
PCR Amplification of GLK and GLKRP cDNA Sequences
[0344] Human GLK and GLKRP cDNA was obtained by PCR from human
hepatic mRNA using established techniques described in Sambrook,
Fritsch & Maniatis, 1989. PCR primers were designed according
to the GLK and GLKRP cDNA sequences shown in Tanizawa et al 1991
and Bonthron, D. T. et al 1994 (later corrected in Warner, J. P.
1995).
Cloning in Bluescript II Vectors
[0345] GLK and GLKRP cDNA was cloned in E. coli using pBluescript
II, (Short et al 1998) a recombinant cloning vector system similar
to that employed by Yanisch-Perron C et al (1985), comprising a
colEI-based replicon bearing a polylinker DNA fragment containing
multiple unique restriction sites, flanked by bacteriophage T3 and
T7 promoter sequences; a filamentous phage origin of replication
and an ampicillin drug resistance marker gene.
Transformations
[0346] E. Coli transformations were generally carried out by
electroporation. 400 ml cultures of strains DHSa or BL21(DE3) were
grown in L-broth to an OD 600 of 0.5 and harvested by
centrifugation at 2,000 g. The cells were washed twice in ice-cold
deionised water, resuspended in 1 ml 10% glycerol and stored in
aliquots at -70.degree. C. Ligation mixes were desalted using
Millipore V series.TM. membranes (0.0025 mm) pore size). 40 ml of
cells were incubated with 1 ml of ligation mix or plasmid DNA on
ice for 10 minutes in 0.2 cm electroporation cuvettes, and then
pulsed using a Gene Pulser.TM. apparatus (BioRad) at 0.5
kVcm.sup.-1, 250 mF, 250 ?. Transformants were selected on L-agar
supplemented with tetracyline at 10 mg/ml or ampicillin at 100
mg/ml.
Expression
[0347] GLK was expressed from the vector pTB375NBSE in E. coli BL21
cells, producing a recombinant protein containing a 6-His tag
immediately adjacent to the N-terminal methionine. Alternatively,
another suitable vector is pET21(+)DNA, Novagen, Cat number 697703.
The 6-His tag was used to allow purification of the recombinant
protein on a column packed with nickel-nitrilotriacetic acid
agarose purchased from Qiagen (cat no 30250).
[0348] GLKRP was expressed from the vector pFLAG CTC (IBI Kodak) in
E. coli BL21 cells, producing a recombinant protein containing a
C-terminal FLAG tag. The protein was purified initially by DEAE
Sepharose ion exchange followed by utilisation of the FLAG tag for
final purification on an M2 anti-FLAG immunoaffinity column
purchased from Sigma-Aldrich (cat no. A1205).
Biotinylation of GLK:
[0349] GLK was biotinylated by reaction with biotinamidocaproate
N-hydroxysuccinimide ester (biotin-NHS) purchased from
Sigma-Aldrich (cat no. B2643). Briefly, free amino groups of the
target protein (GLK) are reacted with biotin-NHS at a defined molar
ratio forming stable amide bonds resulting in a product containing
covalently bound biotin. Excess, non-conjugated biotin-NHS is
removed from the product by dialysis. Specifically, 7.5 mg of GLK
was added to 0.31 mg of biotin-NHS in 4 mL of 25 mM HEPES pH=7.3,
0.15M KCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM MgCl.sub.2 (buffer
A). This reaction mixture was dialysed against 100 mL of buffer A
containing a further 22 mg of biotin-NHS. After 4 hours excess
biotin-NHS was removed by extensive dialysis against buffer A.
Pharmaceutical Compositions
[0350] The following illustrate representative pharmaceutical
dosage forms of the invention as defined herein (the active
ingredient being termed "Compound X"), for therapeutic or
prophylactic use in humans: TABLE-US-00004 (a) Tablet I mg/tablet
Compound X 100 Lactose Ph. Eur 182.75 Croscarmellose sodium 12.0
Maize starch paste (5% w/v paste) 2.25 Magnesium stearate 3.0 (b)
Tablet II mg/tablet Compound X 50 Lactose Ph. Eur 223.75
Croscarmellose sodium 6.0 Maize starch 15.0 Polyvinylpyrrolidone
(5% w/v paste) 2.25 Magnesium stearate 3.0 (c) Tablet III mg/tablet
Compound X 1.0 Lactose Ph. Eur 93.25 Croscarmellose sodium 4.0
Maize starch paste (5% w/v paste) 0.75 Magnesium stearate 1.0 (d)
Capsule mg/capsule Compound X 10 Lactose Ph. Eur 488.5 Magnesium
1.5 (e) Injection I (50 mg/ml) Compound X 5.0% w/v 1M Sodium
hydroxide solution 15.0% v/v 0.1M Hydrochloric acid (to adjust pH =
to 7.6) Polyethylene glycol 400 4.5% w/v Water for injection to
100% (f) Injection II (10 mg/ml) Compound X 1.0% w/v Sodium
phosphate BP 3.6% w/v 0.1M Sodium hydroxide solution 15.0% v/v
Water for injection to 100% (1 mg/ml, (g) Injection III buffered to
pH = 6) Compound X 0.1% w/v Sodium phosphate BP 2.26% w/v Citric
acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection
to 100% (h) Aerosol I mg/ml Compound X 10.0 Sorbitan trioleate 13.5
Trichlorofluoromethane 910.0 Dichlorodifluoromethane 490.0 (i)
Aerosol II mg/ml Compound X 0.2 Sorbitan trioleate 0.27
Trichlorofluoromethane 70.0 Dichlorodifluoromethane 280.0
Dichlorotetrafluoroethane 1094.0 (j) Aerosol III mg/ml Compound X
2.5 Sorbitan trioleate 3.38 Trichlorofluoromethane 67.5
Dichlorodifluoromethane 1086.0 Dichlorotetrafluoroethane 191.6 (k)
Aerosol IV mg/ml Compound X 2.5 Soya lecithin 2.7
Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0
Dichlorotetrafluoroethane 191.6 (l) Ointment ml Compound X 40 mg
Ethanol 300 .mu.l Water 300 .mu.l 1-Dodecylazacycloheptan-2-one 50
.mu.l Propylene glycol to 1 ml Note The above formulations may be
obtained by conventional procedures well known in the
pharmaceutical art. The tablets (a)-(c) may be enteric coated by
conventional means, for example to provide a coating of cellulose
acetate phthalate. The aerosol formulations (h)-(k) may be used in
conjunction with standard, metered dose aerosol dispensers, and the
suspending agents sorbitan trioleate and soya lecithin may be
replaced by an alternative # suspending agent such as sorbitan
monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol
oleate or oleic acid.
REFERENCES
[0351] 1 Printz, R. L., Magnuson, M. A. and Granner, D. K. (1993)
Annual Review of Nutrition 13, 463-96 [0352] 2 DeFronzo, R. A.
(1988) Diabetes 37, 667-87 [0353] 3 Froguel, P., Zouali, H.,
Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage, S.,
Stoffel, M., Takeda, J. and Passa, P. (1993) New England Journal of
Medicine 328, 697-702 [0354] 4 Bell, G. I., Pilkis, S. J., Weber,
I. T. and Polonsky, K. S. (1996) Annual Review of Physiology 58,
171-86 [0355] 5 Velho, G., Petersen, K. F., Perseghin, G., Hwang,
J. H., Rothman, D. L., Pueyo, M. E., Cline, G. W., Froguel, P. and
Shulman, G. I. (1996) Journal of Clinical Investigation 98, 1755-61
[0356] 6 Christesen, H. B., Jacobsen, B. B., Odili, S., Buettger,
C., Cuesta-Munoz, A., Hansen, T., Brusgaard, K., Massa, O.,
Magnuson, M. A., Shiota, C., Matschinsky, F. M. and Barbetti, F.
(2002) Diabetes 51, 1240-6 [0357] 7 Glaser, B., Kesavan, P.,
Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, C. A.,
Thornton, P. S., Permutt, M. A., Matschinsky, F. M. and Herold, K.
C. (1998) New England Journal of Medicine 338, 226-30 [0358] 8
Caro, J. F., Triester, S., Patel, V. K., Tapscott, E. B., Frazier,
N. L. and Dohm, G. L. (1995) Hormone & Metabolic Research 27,
19-22 [0359] 9 Desai, U. I., Slosberg, E. D., Boettcher, B. R.,
Caplan, S. L., Fanelli, B., Stephan, Z., Gunther, V. J., Kaleko, M.
and Connelly, S. (2001) Diabetes 50, 2287-95 [0360] 10 Shiota, M.,
Postic, C., Fujimoto, Y., Jetton, T. L., Dixon, K., Pan, D.,
Grimsby, J., Grippo, J. F., Magnuson, M. A. and Chemington, A. D.
(2001) Diabetes 50, 622-9 [0361] 11 Ferre, T., Pujol, A., Riu, E.,
Bosch, F. and Valera, A. (1996) Proceedings of the National Academy
of Sciences of the United States of America 93, 7225-30 [0362] 12
Seoane, J., Barbera, A., Telemaque-Potts, S., Newgard, C. B. and
Guinovart, J. J. (1999) Journal of Biological Chemistry 274,
31833-8 [0363] 13 Moore, M. C., Davis, S. N., Mann, S. L. and
Chemington, A. D. (2001) Diabetes Care 24, 1882-7 [0364] 14
Alvarez, E., Roncero, I., Chowen, J. A., Vazquez, P. and Blazquez,
E. (2002) Journal of Neurochemistry 80, 45-53 [0365] 15 Lynch, R.
M., Tompkins, L. S., Brooks, H. L., Dunn-Meynell, A. A. and Levin,
B. E. (2000) Diabetes 49, 693-700 [0366] 16 Roncero, I., Alvarez,
E., Vazquez, P. and Blazquez, E. (2000) Journal of Neurochemistry
74, 1848-57 [0367] 17 Yang, X. J., Kow, L. M., Funabashi, T. and
Mobbs, C. V. (1999) Diabetes 48, 1763-1772 [0368] 18 Schuit, F. C.,
Huypens, P., Heimberg, H. and Pipeleers, D. G. (2001) Diabetes 50,
1-11 [0369] 19 Levin, B. E. (2001) International Journal of Obesity
25 [0370] 20 Alvarez, E., Roncero, I., Chowen, J. A., Thorens, B.
and Blazquez, E. (1996) Journal of Neurochemistry 66, 920-7 [0371]
21 Mobbs, C. V., Kow, L. M. and Yang, X. J. (2001) American Journal
of Physiology--Endocrinology & Metabolism 281, E649-54 [0372]
22 Levin, B. E., Dunn-Meynell, A. A. and Routh, V. H. (1999)
American Journal of Physiology 276, R1223-31 [0373] 23 Spanswick,
D., Smith, M. A., Groppi, V. E., Logan, S. D. and Ashford, M. L.
(1997) Nature 390, 521-5 [0374] 24 Spanswick, D., Smith, M. A.,
Mirshamsi, S., Routh, V. H. and Ashford, M. L. (2000) Nature
Neuroscience 3, 757-8 [0375] 25 Levin, B. E. and Dunn-Meynell, A.
A. (1997) Brain Research 776, 146-53 [0376] 26 Levin, B. E., Govek,
E. K. and Dunn-Meynell, A. A. (1998) Brain Research 808, 317-9
[0377] 27 Levin, B. E., Brown, K. L. and Dunn-Meynell, A. A. (1996)
Brain Research 739, 293-300 [0378] 28 Rowe, I. C., Boden, P. R. and
Ashford, M. L. (1996) Journal of Physiology 497, 365-77 [0379] 29
Fujimoto, K., Sakata, T., Arase, K., Kurata, K., Okabe, Y. and
Shiraishi, T. (1985) Life Sciences 37, 2475-82 [0380] 30 Kurata,
K., Fujimoto, K. and Sakata, T. (1989) Metabolism: Clinical &
Experimental 38, 46-51 [0381] 31 Kurata, K., Fujimoto, K., Sakata,
T., Etou, H. and Fukagawa, K. (1986) Physiology & Behavior 37,
615-20
* * * * *